Research
    Xu Rui-hua
    Title Professor and President
    Profile
    Dr. Ruihua Xu is currently a Professor in the Department of Medical Oncology at Sun Yat-Sen University (SYSU) Cancer Center, Guangzhou, China. He specializes in GI medical oncology and is a renowned oncology expert in China. Since 2014 he has also been the President of SYSU Cancer Center. Dr. Xu had been a visiting associate professor in MD Anderson Cancer Center since 2002 to 2005. He is Vice-president of Chinese Society of Clinical Oncology (CSCO), and the Chair of Chinese Medical Oncology Group of Colorectal Cancer . He is the committee member of ASCO.Dr. Xu’s primary research interests include the development of novel drugs for GI cancer, the design and conduct of phase I and II clinical to test these drugs, and transnational research focused on developing prognostic and predictive markers in patients with GI cancer. He has established an international reputation in GI cancer, served as a Steering Committee member in several global trials. He is now leading several clinical trials in China. He has published more than 150 peer-reviewed papers, including some papers in renowned journals such as Journal of Clinical Oncology, Hepatology, Cancer Research, Leukemia, Clinic Cancer Research and Cancer.
    Email xurh@sysucc.org.cn
    Phone +86-20-87343627
    Research Interest(s)
    Development of novel drugs for GI cancer, design and conduct of phase I and II clinical to test these drugs, and transnational research focused on developing prognostic and predictive markers in patients with GI cancer.
    Education

    M.D. School of Medicine, Jiangxi Medical College, China, 1983-1988 

    Master Degree in Oncology, Sun Yat-Sen University of Medical Sciences, China, 1991-1994. 

    Ph.D in Oncology, Sun Yat-Sen University of Medical, China, 1997-2000.

    Publications

    1.   TarohSatoh*, Rui-Hua Xu*equal contribution,Hyun Cheol Chung, Guoping Sun, Toshihiko Doi, Jian-Ming Xu,Chung HC, Sun G, Doi T, Xu JM, AkihitoTsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang, Hiroto Miwa, Shukui Qin, Ik-JooChung, Kun-Huei Yeh, Ji-Feng Feng, Akihira Mukaiyama, Mikiro Kobayashi, AtsushiOhtsu, and Yung-Jue Bang.  Lapatinib plus paclitaxel versus paclitaxelalone in the second-line treatment of HER2-amplified advanced gastric cancer inAsian populations: TyTAN, a randomized, phase III study.  J Clin Oncol.  Accepted. 2014

    2.   ChenDL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH, XuRH*(Correspondence). Identification of miR-214 as a negative regulator of colorectal cancerliver metastasis via regulation of FGFR1expression. Hepatology. 2014 Mar 11. doi: 10.1002/hep.27118.  [Epubahead of print]

    3.   Qiu MZ,Li Q, Wang ZQ, Liu TS, Liu Q, Wei XL, Jin Y, Wang DS, Ren C, Bai L, Zhang DS,Wang FH, Li YH, Xu RH*(Correspondence). HER2-positive patients receiving trastuzumab treatment have a comparableprognosis with HER2-negative advanced gastric cancer patients: A prospectivecohort observation. Int J Cancer. 2013 Oct 23. [Epub ahead of print]

    4.   Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, XuRH*(Correspondence). Overexpression of the circadian clock gene Bmal1increases sensitivity to oxaliplatin in colorectal cancer.  Clin Cancer Res. 2013 Nov 25. [Epubahead of print]

    5.   Qiu MZ, Xu RH*(Correspondence). The progress of targeted therapy in advanced gastriccancer. Biomark Res. 2013 Dec 11;1(1):32. [Epub ahead of print]

    6.   Liu PP,Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, Hu Y, Wang P, Ju HQ, Xu RH,Huang P. Metabolic regulation of cancer cell side population by glucose throughactivation of the Akt pathway. Cell Death Differ. 2014 Jan;21(1):124-35.Epub 2013 Oct 4.

    7.   He MM,Zhang DS, Wang F, Wang ZQ, Luo HY, Jin Y, Wei XL, Xu RH*(Correspondence). The role of non-curative surgery in incurable,asymptomatic advanced gastric cancer. PLoS One. 2013 Dec16;8(12):e83921.

    8.   Qiu MZ,Wei XL, Zhang DS, Jin Y, Zhou YX, Wang DS, Ren C, Bai L, Luo HY, Wang  ZQ,Wang FH, Li YH, Yang DJ, Xu RH*(Correspondence). Efficacy and safety ofcapecitabine as maintenance treatment after first-linechemotherapy using oxaliplatin and capecitabinein advanced gastric adenocarcinoma patients: a prospective observation. Tumour Biol. 2014 Feb 11

    9.   Zhao H,Zeng ZL, Yang J, Jin Y, Qiu MZ, Hu XY, Han J, Liu KY, Liao JW, XuRH*(Correspondence),  Zou QF. Prognostic relevance of Period1 (Per1) andPeriod2 (Per2) expression in human gastriccancer. Int J Clin Exp Pathol. 2014 Jan 15;7(2):619-30. eCollection2014.

    10.  Wei XL, Qiu MZ, Lin HX, Zhang Y, Liu JX, YuHM, Liang WP, Jin Y, Ren C, He MM, Chen WW,Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH*(Correspondence).Patients with old age  or proximal tumors benefit from metabolic syndrome inearly stage gastric cancer. PLoSOne. 2014 Mar5;9(3):e89965.

    11.  Chen DL, Wang ZQ, Ren C, Zeng ZL, Wang DS,Luo HY, Wang F, Qiu MZ, Bai L, Zhang DS, Wang FH, Li YH, XuRH*(Correspondence). Abnormal expression of paxillin correlates with tumorprogression and poor survival in patients with gastric cancer. J Transl Med.2013 Nov 2;11(1):277. [Epub ahead of print]

    12.  He MM, Zhang DS, Wang F, Wang ZQ, Luo HY,Ren C, Jin Y, Chen DL, Xu RH*(Correspondence). Adjuvant chemotherapy, p53, carcinoembryonic antigenexpression and prognosis after D2 gastrectomyfor gastric adenocarcinoma. World J Gastroenterol. 2014 Jan7;20(1):264-73.

    13.  He MM, Wu WJ, Wang F, Wang ZQ, Zhang DS, LuoHY, Qiu MZ, Wang FH, Ren C, Zeng ZL, Xu RH*(Correspondence). S-1-Based Chemotherapy versus Capecitabine-BasedChemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: AMeta-Analysis. PLoS One. 2013 Dec 12;8(12):e82798.

    14.  Chen WW, Wang F, Xu RH*(Correspondence).Platinum-based versus non-platinum-based chemotherapy as first line treatmentof inoperable, advanced gastric adenocarcinoma: a meta-analysis. PLoS One.2013 Jul 11;8(7):e68974.

    15.  Chen DL, Zeng ZL, Yang J, Ren C, Wang DS, WuWJ, Xu RH*(Correspondence). L1cam promotes tumor progression andmetastasis and is an independent unfavorable prognostic factor in gastriccancer. J Hematol Oncol. 2013 Jun 27;6:43.

    16.  Wei XL, Qiu MZ, Chen WW, Jin Y, Ren C, WangF, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH* (Correspondence). The status of HBV infection influences metastaticpattern and survival in Chinese patients with pancreatic cancer. J TranslMed. 2013 Oct 8;11(1):249.

    17. Qiu HB, Zhang LY, Ren C, Zeng ZL, Wu WJ, Luo HY, Zhou ZW, XuRH*(Correspondence). Targeting CDH17 Suppresses TumorProgression in Gastric Cancer by Downregulating Wnt/β-Catenin Signaling. PLoSOne. 2013;8(3):e56959.

    18. Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang DS, Li YH, Xu RH*(Correspondence). Clinicopathologicalcharacteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013 Mar 6;11:58.

    19. Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F,Li YH, Xu RH*(Correspondence). Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabineadministered to Chinese patients with advanced pancreatic cancer. Cancer ChemotherPharmacol. 2013 Apr;71(4):1065-72

    20.  Jin Y, Qiu MZ, Wang DS,Zhang DS, Ren C, Bai L, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH*(Correspondence). Adjuvant chemotherapy forelderly patients with gastric cancer after d2 gastrectomy. PLoS One. 2013;8(1):e53149.

    21. Wu WJ, Zhang Y, Zeng ZL, Li XB, Hu KS, LuoHY, Yang J, Huang P, Xu RH*(Correspondence). Bbeta-phenylethylisothiocyanate reverses platinum-resistance by a GSH-dependent mechanism incancer cells with epithelial-mesenchymal transition phenotype. BiochemicalPharmacology. 2013 Feb15;85(4):486-96.

    22. Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, Ren C,Zhang DS, Wang ZQ, Wang FH, Li YH, Kang TB, ,Xu RH*(Correspondence). Overexpresssion of paxillininduced by miR-137 supression promotes tumor progression and metastasis incolorectal cancer. Carcinogenesis. 2013 Jan 10

    23. Wu WJ, Hu KS, Chen DL, Zeng ZL, Luo HY, WangF, Wang DS, Wang ZQ, He F, Xu RH*(Correspondence). Prognostic relevance of BRD7 expression incolorectal carcinoma. European Journal of Clinical Investigation. 2013Feb;43(2):131-40

    24. Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, Colman H,Keating MJ, Li X, Xu RH, Wang J, Huang P.  Effective Elimination of Cancer Stem Cells bya Novel Drug Combination Strategy. Stem Cells. 2012 Nov 6.

    25.  Xu RH,  Huang P.  A New Role for PHD in Chemotherapy.  Cancer Cell.  2012 Aug 14;22(2):143-4

    26. Wang DS, Wang ZQ, Zhang L, Qiu MZ, Luo HY, Ren C, Zhang DS,Wang FH, Li YH, Xu RH*(Correspondence). Are risk factors associated with outcomes in pancreatic cancer? PLoSOne. 2012;7(7):e41984. Epub 2012 Jul 24

    27. Zeng ZL, Wu WJ, Yang J, Tang ZJ, Chen DL, Qiu MZ, Luo HY,Wang ZQ, Jin Y, Wang DS, Xu RH*(Correspondence) Prognostic relevance ofmelanoma antigen D1 expression in colorectal carcinoma. J Transl Med. 2012 Aug 31;10(1):181

    28. Chen C, Wang FH, Wang ZQ, An X, Luo HY, Zhang L, Chen YC, XuRH, Li YH. Salvage gemcitabine-vinorelbine chemotherapy in patientswith metastatic nasopharyngeal carcinoma pretreated with platinum-basedchemotherapy. Oral Oncol. 2012 Jun 27.

    29. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, XuRH*(Correspondence). Comparison of theprognostic values of various inflammation based factors in patients withpancreatic cancer. Med Oncol. 2012 Apr 5.

    30. Wang F, Yuan S, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS,Rao HL, Xia Y, Jiang WQ, Huang HQ, Xia ZJ, Sun XF, Xu RH*(Correspondence).High hepatitis B virusinfection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev. 2012 May;21(3):261-7.

    31.  Tang Z, Yuan S, Hu Y, Zhang H, Wu W, Zeng Z,Yang J, Yun J, Xu RH*(Correspondence). Over-expression of GAPDH in human colorectal carcinoma as a preferredtarget of 3-Bromopyruvate Propyl Ester. J Bioenerg Biomembr. 2012Feb 18.

    32.  QiuMZ, Qiu HJ, Wang ZQ, Ren C, Wang DS, Zhang DS, Luo HY, Li YH, Xu RH*(Correspondence).The tumor-log odds of positive lymph nodes-metastasis staging system, apromising new staging system for gastric cancer after d2 resection in china. PLoSOne. 2012;7(2):e31736. Epub 2012 Feb 14.

    33. Zhang L, Wang LY, Deng YM, Wang FH, Feng F, Chen YC, An X,Chen C, Xu RH, Li YH. 12.Efficacy of the FOLFOX/CAPOX regimen foradvanced small bowel adenocarcinoma: a three-center study from China. J BUON.2011 Oct-Dec;16(4):689-96.

    34.  LiZH, Qiu MZ, Zeng ZL, Luo HY, Wu WJ, Wang F, Wang ZQ, Zhang DS, Li YH, Xu RH*(Correspondence).Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated withplatinum-resistance in non-small cell lung cancer (NSCLC). J Transl Med. 2012Feb 3;10(1):21.

    35.  RenC, Qiu MZ, Wang DS, Luo HY, Zhang DS, Wang ZQ, Wang FH, Li YH, Zhou ZW, XuRH*(Correspondence).Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. JTransl Med. 2012 Jan 27;10(1):16.

    Jiang Wenqi
    Title Professor of Medical Oncology, Director of the Department of Medical Oncology
    Profile Dr. Jiang received his MD from Shanghai Medical University in 1982 and his Master of Science in Oncology from Sun Yat-sen University of Medical Sciences in 1988. He completed his clinical training in Internal Medicine at the Shanghai Medical University and in Medical Oncology in the  Sun Yat-sen University of Medical Sciences. Then he joined the research group of Dr. Zhongzen Guan, where he played a major role in development and evaluation of new anti-cancer drugs.

    For a number of years, Dr. Jiang research has been focused on the developing and evaluation of new anti-cancer drugs. Dr. Jiang has been taking part in the research on developing some new anti-cancer drugs and has conducted several phase I and phase II clinical trial of new anti-cancer  drugs produced by both domestic and oversea pharmaceutical companies.

    During 1995-1997, Dr. Jiang studied clinical pharmacology in the University of Alabama at  Birmingham as a visiting scholar and received further clinical training in MD Anderson Cancer Center.

    Currently Dr. Jiang is focusing on developing a new anti-cancer drugs which can induce the difference and promote the apoptosis of cancer cells, and has the function to reverse multi-drug resistance. This drug is going to enter phase I clinical trial in China recently.

    Email wqjiang@yahoo.com
    Phone
    Research Interest(s)
    Education
    Publications
    1. pharmocokinetics and clinical study of Two-route-chemotherapy using high dose cisplatin intrapleurally with thiasulfateintravenously.

    Chinese Journal of Cancer, 1989, 4(2): 149-154

     

    2. Phase I and II clinical trial of carboplatin.

    Chinese Journal of Cancer, 1993, 6(3): 116-120

     

    3. The role of neupogen (rhG-CSF) in high dose chemotherapy.

    Chinese Journal of Cancer, 1993, 12(6): 176-182

     

    4. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implications in fluorouracil-based chemotherapy.

    Clinical Cancer Research, 1997, 3(3): 395-399.

    Zhang Li
    Title Professor, Vice Chair, Director of National Clinical Study (GCP) Center for anti-cancer drugs and Director of Phase I unit
    Profile
    Professor Li Zhang is the Professor of Medical Oncology, Deputy Director of Lung Cancer Research Centre of Sun Yat-Sen University (SYSU) and the Department of Medical Oncology at the Sun-Yat Sen University Cancer Centre (SYSUCC). He is also the member of ASCO, CSCO, ESMO, IASLC and Board Member of communication committee of IASLC. He contributes extensively to the Chinese Anti-Cancer Association where he currently serves as vice chairman of the Association of Rehabilitation and Palliative Care, CACA, vice chairman of both the Cancer Chemotherapy Association and Lung Cancer Association of the Guangdong Province. He is also a standing committee member of the Chinese Society of Clinical Oncology (CSCO). He had published more than 60 clinical research papers in peer review journals like JCO, Lancet Oncology, Annals of Oncology, Cancer, Journal Thoracic Oncology, Lung Cancer, Support Care Cancer and presenting abstracts to many major congresses like ASCO, AACR, WCLC, ESMO meetings. At present, he is a senior consultant to the Centre of Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA) and had formerly drafted the CFDA Guidance for Industry: Clinical Trial for the Approval of Cancer Drugs and Biologics (second version, 2006).
    Email zhangli6@mail.sysu.edu.cn
    Phone 86-20-8734-2288
    Research Interest(s)
    Dr Zhang’s research is focused on developing molecular, prognostic and therapeutic approaches to improve the care for patients with lung cancer, colorectal cancer and nasopharyngeal carcinoma (NPC). His research interesting also including supportive care like treatment of chemotherapy induced anaemia (CIA), chemotherapy induced nausea and vomiting (CINV),bone metastases, pain ect. He is the member of the NCCN Clinical Practice Guidelines in Oncology™ (Chinese Version) Lung Cancer, Colon/Rectal Cancer and Head and Neck Cancer Panel. He has been extensively involved in many Phase I studies of novel agents and phase III trials, as globe principle investigator (PI) and/or steering committee member. Currently He is conducting several randomized clinical trials on Lung cancer and NPC as principle investigator (PI) and has established a huge sample bank of tumor, blood, etc.
    Education
    After receiving his medical degree from Sun Yat-Sen University (1980-1986), Professor Zhang continued his postgraduate training at SYSUCC where he completed a master’s degree in clinical oncology (1988-1991) and then worked as an Attending Doctor and Associate Professor before being appointed to his current position. Professor Zhang has undertaken training courses at the Gustave Roussy Institute in Paris, France (1996), and at the Fox Chase Cancer Center in Philadelphia, US (1998). He was also a Visiting Fellow at the University of Texas M.D. Anderson Cancer Center in Houston, US (2001-2002).
    Publications

    1. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.: Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004; Vol 100(6): 1162-1170 (SCI=4.8)

    2. Chen M, Chen YY, Bao Y, Xian CG, Liu GZ, Zhang L, Xu GC, Deng XW, Lu TX, Qian JY, Cui NJ.: Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial. Clinical Lung Cancer 2005; Vol 6(5): 304-309

    3. Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, Wu SX.: Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. Journal of Clinical Oncology 2005; Vol 23(33): 8461-8468 (SCI=11.9)

    4. Mok TS, Lam KC, Lee C, Zhang L, Wong H, Chan AT, Yeo W, Yim AP, Chak K, Zee B.: Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Oncology 2005; Vol 68(4-6): 485-492 (SCI=1.9)

    5. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.: Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; Vol 106(6): 1320-1325 (SCI=4.58)

    6. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T.: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. Journal of Thoracic Oncology 2007; Vol 2(5): 430-439 (SCI=1.43)

    7. Zhang L, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ.: Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemotherapy Pharmacology 2008; Vol 61(1): 33-38 (SCI=2.2)

    8. Hui-Yan Luo, Rui-Hua Xu, Li Zhang, Yu-Hong Li, Yan-Xia Shi, Tong-Yu Lin, Bing Han, Feng Wang, Miao-Zhen Qiu, You-Jian He, Zhong-Zhen Guan: A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer.  Chemotherapy 2008; Vol 54: 228-235 (SCI=1.50)

    9. Tony Mok, Yi-Long Wu, Chong-Jen Yu, Caicun Zhou, Yuh-Min Chen, Li Zhang, Jorge Ignacio, Meilin Liao, Vichien Srimuninnimit, Michael J Boyer, Marina Chua-Tan, Virote Sriuranpong, Aru W Sudoyu, Kate Jin, Michael Johnston, Winsome Chui, Jin-Soo Lee: Randomized, Placebo-controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2009; Vol 27: 5080-5087 (SCI=17.3)

    10. Xu Fei, Li Su, Li Xiao-ling, Guo Ying, Zou Ben-Yan, Xu Ran, Liao Hai, Zhao Hong-Yun, Guan Zhong-Zhen, Zhang Li: Phase I study of Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and Ganciclovir administration in patients with malignant tumor.  Cancer Gene Therapy 2009; Vol 16: 723-730 (SCI=3.89)

    11. Mok T, Wu YL, Zhang L: A small step towards personalized medicine for non-small cell lung cancer.  Discov Med. 2009; Vol 8(43): 227-231 (Review)

    12. Li Zhang, Xue Hou, Shun Lu, Huilan Rao, Jinghui Hou, Rongzhen Luo, He Huang, Hongyun Zhao, Hong Jian, Zhiwei Chen, Meilin Liao, Xin Wang: Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study. Lung Cancer 2010; Vol 67: 114-119 (SCI=3.14)

    13. Tony Mok, Keunchil Park, Joseph Siu-kie Au, Caicun Zhou, Li Zhang, Reury-Perng Perng, and Yi-long Wu: Efficacy and Safety of Erlotinib in >1200 East/South-East Asian Patients with Advanced Non-Small-Cell Lung Cancer.  Journal of Thoracic Oncology 2010; Vol 5: 1609–161 (SCI=4.547)

    14. Fenghua Wang, Yang Zhang, Hongyun Zhao, Likun Chen, Yan-Xia Shi, Li Zhang: Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.  Medical Oncology 2010; Vol 28 (1): 331-335 (SCI=1.227)

    15. Yuan-Yuan Zhao, Su Li, Yang Zhang, Hong-Yun Zhao, Hai Liao, Ying Guo, Yan-Xia Shi, Wei Jiang, Cong Xue, Li Zhang: The Relationship between Drug Exposure and Clinical Outcomes of Non-Small Cell Lung Cancer Patients Treated with Gefitinib. Medical Oncology 2010; Vol 28(3): 697-702 (SCI=1.227)

    16. Fenghua Wang, Fanggong Jiang Yuhong Li, Ying Guo, Lin Shen and Li Zhang: The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in Advanced Gastric Cancer: A Systematic Review and Pooled Analysis of the Chinese Literature. Current Cancer Therapy Reviews 2010; Vol 6 (3):214-221

    17. Roy S Herbst, Yan Sun, Wilfried EE Eberhardt, Paul Germonpré, Nagahiro Saijo, Caichun Zhou, Jie Wang, Longyun Li, Fairooz Kabbinavar, Yukito Ichinose, Shukui Qin, Li Zhang, Bonne Biesma, John V Heymach, Peter Langmuir, Sarah J Kennedy, Hiroomi Tada and Bruce E Johnson: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer: a randomised, double-blind phase III trial (ZODIAC).  Lancet Oncology 2010;Vol 11: 619-626 (SCI= 14.47)

    18. Li Zhang, Chong Zhao, Bijesh Ghimire, Ming-Huang Hong, Qing Liu, Yang Zhang, Ying Guo, Yi-Jun Huang, Zhong-Zhen Guan:The Role of Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma among Endemic Population: A Meta- analysis of the Phase III Randomized Trials.  BMC Cancer 2010; Vol 10: 558 (SCI=3.15)

    19. Liang-ping Xia; Hui-juan Qiu; Xu-xian Chen; Pi-li Hu; Gui-fang Guo; Fang Wang; Fei-fei Zhou; Wen-zhuo He; Bei Zhang; Li Zhang: Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Medical Oncology 2010 Vol 28(1):570-576 (SCI=1.227)

    20. Li Zhang, Su Li, Yang Zhang, Jing Zhan, Ben-Yan Zou, Robert Smith, Paul D Martin, Yinrui Jiang, Hai Liao, Zhong-zhen Guan: Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumours: An Open-Label, Phase I, Rising Multiple Dose Study. Clinical Therapeutics, 2011; Vol 33(3):315–327(SCI=3.28)

    21. Xue Hou, Chong Zhao, Ying Guo, Fei Han, Li-Xia Lu, Shao-Xiong Wu, Su Li, Pei-Yu Huang, He Huang, Li Zhang: Different Clinical Significance of Pre- and Post-treatment Plasma Epsteine Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy.  Clinical Oncology 2011; Vol 23: 128-133 (SCI==2.85)

    22. Yuan-Yuan Zhao, Cong Xue, Xue Hou, Hai Liao, Su Li, Hong-Yun Zhao, Yan Huang, Li-Kun Chen, Fei Xu, Jun-Ling Liu, Li Zhang:Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. European Journal of Cancer 2011; Vol 47: 848-853 (SCI=4.47)

    23. Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, Li Zhang, Changxuan You: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology 2011;Vol 12:735-742  (SCI= 17.76)

    24. An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH : Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.  Cancer 2011; Vol 117(16):3750-3757 (SCI=5.131)

    25. Yuan-Yuan Zhao, Cong Xue, Wei Jiang, Hong-Yun Zhao, Yan Huang, Kristin Feenstra, James H. Resau, Chao-Nan Qian, Li Zhang: Predictive Values of Intratumoral Microvascular Density (MVD) in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy plus Bevacizumab. Journal of Thoracic Oncology 2012; Vol 7 (1):71-75 (SCI=3.66)

    26. Hu X, Bao Y, Zhang L, Guo Y, Chen YY, Li KX, Wang WH, Liu Y, He H, Chen M:                 Omitting elective nodal irradiation and irradiating post-induction versus pre-induction chemotherapy tumor extent for limited-stage small cell lung cancer: Interim analysis of a prospective randomized non-inferiority trial.  Cancer 2012; Vol 118 (1):278-287 (SCI= 5.131)

    27. Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, Zhao LP, Tian Y: Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem. 2012, Vol 113(5):1501-1513. (SCI= 3.12)

    28. Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M : Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Non-squamous Non-small Cell Lung Cancer: An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial.  Journal of Thoracic Oncology 2012; Vol 7(3):567-573 (SCI=4.47)

    29. Li Zhang, Shenglin Ma, Xiangqun Song, Baohui Han, Ying Cheng, Cheng Huang, Shujun Yang, Xiaoqing Liu, Yunpeng Liu, Shun Lu, Jie Wang, Shucai Zhang, Caicun Zhou, Xiangwei Zhang, Nobuya Hayashi, Mengzhao Wang: Efficacy and tolerability data from a randomised, placebo-controlled, parallel-group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).  Lancet Oncology 2012;Vol 13:466-475 (SCI=22.589)

    30. Mian Xie, Li Zhang, Chao-Sheng He, Jin-Hui Hou, Su-Xia Lin, Zhi-Huang Hu, Fei Xu and Hong-Yun Zhao: Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer.  Journal of Thoracic Oncology 2012; Vol 7(5):799-807 (SCI=4.47)

    31. Luis Paz-Ares, Bonne Biesma, David Heigener, Joachim von Pawel, Timothy Eisen, Jaafar Bennouna, Li Zhang, Meilin Liao, Yan Sun, Assad Chemaissani, SJM Gans, Constantinos Syrigos, Etienne Le Marie, Maya Gottfried, Johan Vansteenkiste, Vincente Alberola, Uwe Phillip Strauss, Elaine Montegriffo, Teng Jin Ong, Armando Santoro, on behalf of the NExUS Investigators Study Group: Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/ Cisplatin Alone or with Sorafenib for the First-Line Treatment of Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology 2012; Vol 30:3048-3092 (SCI=18.37)

    32. Pei-Yu Huang, Yan Li, Hai-Qiang Mai, Rong-Zhen Luo, Yu-Chen Cai, Li Zhang: Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.  Oral Oncology 2012; Vol 48(10):964-968 (SCI=2.857)

    33. Cong Xue, Zhihuang Hu, Wei Jiang, Yuanyuan Zhao, Fei Xu, Yan Huang, Hongyun Zhao, Jingxun Wu, Yang Zhang, Liping Zhao, Jing Zhang, Likun Chen, Li Zhang: National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China.  Lung Cancer 2012; Vol 77(2):371-375 (SCI=3.43)

    34. Cong Xue, Xi Wang, Roujun Peng, Yanxia Shi, Tao Qin, Donggen Liu, Xiaoyu Teng, Shusen Wang, Li Zhang and Zhongyu Yuan: Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.  Cancer Science 2012; Vol 103(9):1679-1687 (SCI=3.325)

    35. Jianwei Zhang, Yan Huang, Xiaoling Li, Ying Guo, Yuanyuan Zhao, Cong Xue, Zhihuang Hu, Li Zhang, Hongyun Zhao: The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution. Onco Targets and Therapy 2012, Vol 5:349–355 (SCI=1.26)

    36. Fei Xu, Jingxun Wu, Yuanyuan Zhao, Cong Xue, Wei Jiang, Liping Lin, Xuan Wu, Yachao Lu, Hua Bai, Jiasen Xu, Guanshan Zhu, Li Zhang: Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets and Therapy 2012, Vol 5:439-447 (SCI=1.26)

    37. Yan Huang, Jing Zhang, Yuan-Yuan Zhao, Wei Jiang, Cong Xue, Fei Xu, Hong-Yun Zhao, Yang Zhang, Li-Ping Zhao, Zhi-Huang Hu, Zhi-Wen Yao, Qian-Yong Liu and Li Zhang: SPARC expression and prognostic value in non-small cell lung cancer.  Chinese Journal of Cancer 2012; Vol 31(11):541-548

    38. Yang Zhang, Liping Zhao, Peiyu Huang, Jingxun Wu, Fenghua Wang, Yan Huang, Li Zhang: Open-Label Single-Arm Phase II Study of Pemetrexed in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Had Prior Platinum Based Chemotherapy. Cancer Chemotherapy and Pharmacology 2012; Vol 70(4):611-615 (SCI=2.2)

    39. Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M.: Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol. 2012; Vol 8(3):232-243 (SCI=0.58)

    40. Yin-Duo Zeng, Li Zhang, Hai Liao, Ying Liang, Fei Xu, Jun-Ling Liu, Xiao-Xiao Dinglin, Li-Kun Chen: Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pacific journal of cancer prevention 2012; Vol 13(3):909-914.(SCI=0.66)

    41. Hongyun Zhao, Yan Huang, Cong Xue, Yang Chen, Xue Hou, Ying Guo, Liping Zhao, Zhi huang Hu, Yujie Huang, Yongzhang Luo, Li Zhang: Prognostic significance of cell surface nucleolin expression in postoperative non-small cell lung cancer. PLoS One 2013, Vol 8(1):e54674 (SCI=3.73)

    42. C. Xue, Y. Huang, P. Y. Huang, Q. T. Yu, J. J. Pan, L. Z. Liu, X. Q. Song, S. J. Lin, J. X. Wu, J. W. Zhang, H. Y. Zhao, F. Xu, J. L. Liu, Z. H. Hu, L. P. Zhao, Y. Y. Zhao, X Q . Wu, J. Zhang, Y. X. Ma, & L. Zhang:Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.  Annals of Oncology 2013; Vol 24:1055-1061 (SCI=7.384)

    43. Y. Sun, Y.-L. Wu, C.-C. Zhou, L. Zhang, L. Zhang, X.-Y. Liu, S.-Y. Yu, G.-L. Jiang, K. Li, S.-K. Qin, S.-L. Ma, L. Han, M. Quinlivan, M. Orlando, X.-Q. Zhang: Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study. Lung Cancer 2013; Vol 79(2):143-50 (SCI=3.43)

    44. Fang Wang, Sha Fu, Qiong Shao, Yan-Bin Zhou, Xiao Zhang, Xu Zhang, Cong Xue, Jian-Guang Lin, Li-Xia Huang, Li Zhang, Wei-Min Zhang and Jian-Yong Shao:High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.  Journal of Translational Medicine 2013, Vol 11:90 (SCI=3.47)

    45. Yi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, Chong-Jen Yu, Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Fatima Fuerte, Gee-Chen Chang, Kasan Seetalarom, Jie Wang, Ashley Cheng, Elisna Syahruddin, Xiaoping Qian, James Ho, Johan Kurnianda, Hsingjin Eugene Liu, Kate Jin, Matt Truman, Ilze Bara, Tony Mok: Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.  Lancet Oncology 2013;Vol 14(8):777-786 (SCI=25.117)

    46. Hongyun Zhao, Yuanyuan Zhao, Ying Guo, Yan Huang, Suxia Lin, Cong Xue, Fei Xu, Yang Zhang, Liping Zhao, Zhihuang Hu, Li Zhang: Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment.  Onco Targets and Therapy 2013; Vol 6:811-818 (SCI=2.073)

    47. G. Chen, J. Feng, C. Zhou, Y.-L. Wu, X.-Q. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang, C.-P. Hu, C. Hu, Y. Luo, L. Chen, M. Ye, J. Huang, X. Zhi, Y. Zhang, Q. Xiu, J. Ma, L. Zhang & C. You: Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).  Annals of Oncology 2013; Vol 24(6):1615-1622 (SCI=7.384)

    48. X. Wu, P. Y. Huang, P. J. Peng, L. X. Lu, F. Han, S. X. Wu, X. Hou, H. Y. Zhao, Y. Huang, W. F. Fang, Y. Y. Zhao, C. Xue, Z. H. Hu, J. Zhang, J. W. Zhang, Y. X. Ma, W. H. Liang, C. Zhao, L. Zhang: Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.  Annals of Oncology 2013; Vol 24(8):2131-2136 (SCI=7.384)

    49. Yuankai Shi*, Li Zhang*, Xiaoqing Liu, Caicun Zhou, Li Zhang, Shucai Zhang, Dong Wang, Qiang Li, Shukui Qin, Chunhong Hu, Yiping Zhang, Jianhua Chen, Ying Cheng, Jifeng Feng, Helong Zhang, Yong Song, Yi-Long Wu, Nong Xu, Jianying Zhou, Rongcheng Luo, Chunxue Bai, Yening Jin, Wenchao Liu, Zhaohui Wei, Fenlai Tan, Yinxiang Wang, Lieming Ding, Hong Dai, Shunchang Jiao, Jie Wang, Li Liang, Weimin Zhang, Yan Sun: Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.  Lancet Oncology 2013; Vol 14:953-961 (SCI=25.117)

    50. Wenfeng Fang, Jianwei Zhang, Wenhua Liang, Yan Huang, Yue Yan, Xuan Wu, Zhihuang Hu, Yuxiang Ma, Hongyun Zhao, Yuanyuan Zhao, Yunpeng Yang, Cong Xue, Jing Zhang, Li Zhang: Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation.  J Thorac Dis 2013; Vol 5(5):585-592

    51. Mian Xie, Chao-Sheng He, Shen-Hai Wei, Li Zhang: Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur J Cancer 2013; Vol 49(16):3559-3572. (SCI=4.12)

    52. Ming-Yuan Chen, Rou Jiang, Ling Guo, Xiong Zou, Qing Liu, Rui Sun, Fang Qiu, Zhong-Jun Xia, Hui-Qiang Huang, Li Zhang, Ming-Huang Hong, Hai-Qiang Mai, Chao-Nan Qian: Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chinese journal of cancer 2013; Vol 32(11):604-613.

    53. Jian-Wei Zhang, Yuan-Yuan Zhao, Ying Guo, Cong Xue, Zhi-Huang Hu, Yan Huang, Hong-Yun Zhao, Jing Zhang, Xuan Wu, Wen-Feng Fang, Yu-Xiang Ma, Li Zhang: The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of advanced non--small cell lung cancer.  Chinese journal of cancer 2014; Vol 33(2):105-114

    54. Zhihuang Hu, Ying Cheng, Hongyu Zhang, Caicun Zhou, Baohui Han, Yiping Zhang, Cheng Huang, Jianhua Chang, Xiangqun Song, Jun Liang, Houjie Liang, Chunxue Bai, Shiying Yu, Jia Chen, Jie Wang, Hongming Pan, Denesh K. Chitkara, Darcy A. Hille, Li Zhang: Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.  Support Care Cancer 2014; Vol 22:979–987. (SCI=2.649)

    55. Wenhua Liang, Xuan Wu, Wenfeng Fang, Yuanyuan Zhao, Yunpeng Yang, Zhihuang Hu, Cong Xue, Jing Zhang, Jianwei Zhang, Yuxiang Ma, Ting Zhou, Yue Yan, Xue Hou, Tao Qin, Xiaoxiao Dinglin, Ying Tian, Peiyu Huang, Yan Huang, Hongyun Zhao, Li Zhang: Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. PLoS ONE 2014; Vol 9(2):e85245. (SCI=3.73)

    56. Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Xue Hou, Ying Tian, Yuanyuan Zhao, Cong Xue, Wenfeng Fang, Xuan Wu, Zhihuang Hu, Wenhua Liang, Ting Zhou, Tao Qin, Li Zhang: An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System.  Lung cancer 2014; Vol 84(3):301-316 (SCI=3.14)

    57. Qing Zhou, Cai-Cun Zhou, Gong-Yan Chen, Ying Cheng, Cheng Huang, Li Zhang, Chong-Rui Xu, Ai-Wu Li, Hong-Hong Yan, Jian Su, Xu-Chao Zhang, Jin-Ji Yang, Yi-Long Wu: A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). Lung cancer 2014; Vol 83(3):369-373 (SCI=3.14)

    58. Hong-Yun Zhao, Guo-Wei Ma, Ben-Yan Zou, Mei Li, Su-Xia Lin, Li-Ping Zhao, Ying Guo, Yan Huang, Ying Tian, Dan Xie, Li Zhang: Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients.  Onco Targets and Therapy 2014; Vol 7:1301-1310 (SCI=2.073)   

     
    Huang Huiqiang
    Title Professor, doctoral advisor, Deputy Director of Medical Oncology
    Profile
    After receiving a Bachelor’s Degree from former Sun Yat-sen University of Medical Sciences in 1984, Prof. Huang Huiqiang has been engaged himself in clinical work and specializes in common cancer chemotherapy, especially chemotherapy of lymphoma and nasopharynx carcinoma, transplantation of hematopoietic stem cells, recurrent or refractory lymphoma, childhood cancer, germ cell tumor, small cell lung cancer (SCLC) and other tumors in the University. In 2000 and 2004, he went to Fred Hutchinson Cancer Research Center in the US and Australia for short-term studies. Presently, he is the drug evaluation consultant of State Food and Drug Administration (SFDA), and Deputy Director of Lymphoma Committee of Guangdong Province Anti-cancer Association, Deputy Director of Blood Tumor Committee of Guangdong Province Anti-cancer Association and Member of the American Society of Hematology (ASH).
    Email huang_sysu@163.com
    Phone
    Research Interest(s)
    Education
    Publications

    The Preliminary Results of Advanced and Recurrent Malignant Lymphoma Treated by BEAC Regimen Supported with Autologous Hematopoietic Stem Cells Transplantation Chinese Huang Hui-qiang et al. Journal of Cancer Research(CJC) 2002 14(1):50-53

    Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin’s lymphoma :single institution experience Bufei Wang ,Huiqiang Huang The Chinese-German Journal of Clinical Oncology 2006 Dec Vol5 Num 6(402)

    Phase II clinical trial of Lopaplatin in the treatment of solid malignancies Jiang wen- qi Lin Tong-yi Huang Hui-qiang et al : International Journal of Modern Cancer Therapy 1999,33:312-5

    Novantrone:A phase II trial in the treatment of advanced nasopharyngeal carcinoma in the People’s Republic of China Z.Z. Guan, H.Q. Huang , R. Rastogi Proceedings of American Society of Clinical Oncology(ASCO) 1993 : 12 (5) abstract 922

     

    Shusen Wang
    Title Professor
    Profile Work experience
    2013.01-present    Professor, Department of medical oncology, Cancer center of Sun Yat-sen University, China

    2010.08 -2010.12    Clinical observer, Breast Cancer Medicine service

    Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA

    2007.01-2012.12   Associate professor,

    Department of medical oncology,

    Cancer center of Sun Yat-sen University, China

    2004.07- 2006.12   Lecturer & Attending Physician,

    Department of medical oncology,

    Cancer center of Sun Yat-sen University, China

    1998.07 -2001.08    Lecturer & attending physician,

    Affiliated hospital of Xuzhou Medical College, China

    1992.07 -1995.08    Resident physician,

    Affiliated hospital of Xuzhou Medical College, China

    Email wangshs@sysucc.org.cn
    Phone +86-20-87342491 (Office) +86-13926168469
    Research Interest(s)

    1. Familiar with medical oncology and phase I, II, III Clinical trials

    2. Cell culture and purification of protein. 

    3. In vitro and in vivo study of anti-cancer drugs

    4. Molecular biological techniques

    Education

    2001-2004 Ph.D. in Medical Oncology, Sun Yat-sen University, China

    1995-1998 M.S. in Medical Oncology, Henan Medical University, China 

    1987-1992 M.D. in Clinical Medicine, Xuzhou Medical College, China

    Publications

    1.       Fu L, Shi K, Wang J, ChenW, Shi D, Tian Y, Guo W, Yu W, Xiao X, Kang T, Wang S, Huang W, Deng W. TFAP2B overexpressioncontributes to tumor growth and a poor prognosis of human lung adenocarcinomathrough modulation of ERK and VEGF/PEDF signaling. Mol Cancer,2014,13:89  (corresponding author)

    2.       Chen W, Qin L, Wang S, Li M, Shi D, Tian Y, Wang J, FuL, Li Z, Guo W, Yu W, Yuan Y, Kang T, Huang W, Deng W. CPSF4 activates telomerasereverse transcriptase and predicts poor prognosis in human lungadenocarcinomas. Mol Oncol. 2014May;8(3):704-716  (correspondingauthor)

    3.       ZENG Yin-duo, XU Fei, QIN Tao,YANG Yan-hua,LIAO Yu-ting,Qin Ge,Wang Shu-sen. Toremifene inPostmenopausal Operable Patients with Luminal Subtype of Breast Cancer asCompared with Tamoxifen:A Retrospective Study in China. Chin J Bases ClinGeneral Surg,  2014,21( 5):555-561(correspondingauthor)

    4.       Ma hongmin,Hu lingyu, Wang shusen.Diagnosis and Treatment for Occult Breast Cancer. Chin J BasesClin General Surg, 2014, 21( 5):544-548(corresponding author) 

    5.       Qin T, Yuan ZY, PengRJ,Zeng YD,Shi YX, Teng XY,Liu DG, Bai B, WangSS .Efficacy andtolerability of toremifene and tamoxifen therapy in premenopausal patients withoperable breast cancer: a retrospective analysis. Curr Oncol,2013, 20(4):1-9  (correspondingauthor)

    6.        Qin T, Yuan ZY, Peng RJ ,Shi YX, Teng XY,LiuDG, Bai B, Wang SS .HER2-positive breast cancer patients receivingtrastuzumab treatment obtain prognosis comparable with that ofHER2-negativebreast cancer patients. Onco Targets and Therapy.2013,6:341-47   (corresponding author)

    7.       QIN Tao, YUAN Zhong-yu, PENGRou-jun, BAI Bing, SHI Yan-xia, TENG Xiao-yu, LIU Dong-geng, WANG Shu-sen. Efficacy and Safety of Toremifene in Young Patients with LuminalSubtype Early Breast Cancer: A Retrospective Study. JOURNAL OF SUN YAT-SEN UNIVERSITY(MEDICAL SCIENCES),2013,34(3):402-406(corresponding author)

    8.       Fu ly, Chen WB, Guo W, WangJS, Tian Y, Shi DB, Zhang XH,Qiu HJ, Xiao XS, Kang TB, Huang WL, Wang SS,Deng WG.Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF andCytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. PIOS ONE,2013,8(7):1-13  (correspondingauthor)

    9.       Gu WG, Huang Y, YuanZY, Peng RJ, Luo HT, He ZR, Wang SS. ZD1839 and cisplatin aloneor in combination for treatment of a nasopharyngeal carcinoma cell line andXenografts. Asian Pac J Cancer Prev. 2013;14(3):1787-90 (correspondingauthor)

    10.   Wangbing Chen, Wei Guo, Mei Li, Dingbo Shi, Yun Tian, Zhenlin Li,Jingshu Wang, Lingyi Fu, Xiangsheng Xiao, Quentin Qiang Liu, Shusen Wang, Wenlin Huang, Wuguo Deng. Upregulation of cleavageand polyadenylation specific factor 4 in lung adenocarcinoma and its criticalrole for cancer cell survival and proliferation. PLoS One. 2013;8(12):e82728 (corresponding author)

    11.    Wang S, Shi Y,Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. ClassicalCMF regimen as adjuvant chemotherapy for triple-negative breast cancer may bemore effective compared with anthracycline or taxane-based regimens. Med Oncol.2012,29:547-553 (first author)

    12.    He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgenreceptor expression in operable triple negative breast cancer: A retrospectiveanalysis based on a tissue microarray. Med Oncol 2012,29:406-410

    13.     Liu D, He J,Yuan Z, Wang S, Peng R, Shi Y, TengX, Qin T. EGFR expression correlates with decreased disease-free survival intriple negative breast cancer: A retrospective analysis based on a tissuemicroarray. Med Oncol. 2012,29:401-405

    14.   Shi YX, Tan YT,Yuan ZY, Wang SS, Peng RJ, An X, CaoY, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. Comparison of overall survivalbetween the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breast cancer.Med Oncol 2012,29:39-47

    15.   Shi YX, Xia Q,Peng RJ, Yuan ZY, Wang SS, An X, CaoY, Tan YT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer. J Cancer Res Clin Oncol. 2012 ,138:705-714

    16.    Wang x, Wang SS,Peng RJ, Qin T, Shi YX, Teng xy, Chen wq, Liu DG,  Yuan ZY. Interaction of coping styles andpsychological stress on anxious and depressive symptoms in Chinese breastcancer patients. Asian Pacific J Cancer Prev 2012; 13:1645-1649. (IF:1.24)

    17.   PengR, Wang S, Shi Y, Liu D, Teng X, QinT, Zeng Y, Yuan Z. Patients 35 years old oryounger with operable breast cancer are more at risk for relapse and survival:A retrospective matched case-control study. Breast. 2011; 20: 568-573.(IF:2.089)

    18.    Liu DG, WangSS, Peng RJ, Qin T, Shi YX, Teng XY, Wang X, Chen WQ, Yuan ZY. Interaction of Social Support andPsychological Stress on Anxiety and Depressive Symptoms in Breast CancerPatients. Asian Pacific J Cancer Prev 2011; 12:2523-2529. (IF:1.24)

    19.   Bing Bai, Shusen Wang et al. Clinical Featuresand Survival Analysis of Different  Subtypesof   Patients with Breast Cancer BrainMetastases. Chinese Journal of Cancer, 2010,29(4): 453-461. (corresponding author)

    20.   Qin jianyong Wang shusen,YIN CHUANZHONG The legaland ethic issues in operating medical information service website. JOURNAL OFMEDICAL INFORMATICS,2010,31(8):52-55

    21.   Yuan zhongyu,Shusen Wang, et al.  Clinical Characteristics and Prognosis ofTriple-Negative Breast Cancer: A Report of 305 Cases. Chinese Journal ofCancer, 2008, 27(6)..

    22.   Yuan zhongyu,Shusen Wang, et al. Clinical characteristics and prognosis ofdifferent subtypes of breast cancer Chinese Journal of Oncology.  2008 ,30(6):456-61

    23.   Fu xiaohong, Wang shusen, Huang yan,el al. Prognostic significance of CD20expression in Hodgkin and Reed-sternberg cells of classical hodgkin’s lymphoma.Chinesr journal of cancer 2008,27(11):1197-1203

    24.   CAO Ya –Bing, WANG Shu-Sen, HUANG Hui-Qiang et al.Primary Breast Lymphoma —A Report of 27 Cases withLiterature Review Chinese Journalof Cancer, 2007, 26( 1) : 84- 89

    25.   Xiao Jian, Wang Shusen, Huang Yan et al.  Expression of CD117 and PDGFRa in ExtranodularNK/T Cell Lymphoma (Nasal Type) .Chinese Journal of Clinical Oncology2,007 34(11):615-617

    26.   QIU Miao-Zhen, XUFei, WANG Shu-Sen et al.Responses of 109 Adult Soft Tis sue Sarcoma Patientsto Chemotherapy .Chinese Journal of Cancer, 2007, 26( 12) : 1344- 1349

    27.    Shusen Wang, Zhongzhen Guan, et al. The Significance of EGFR and p-ERK Expressionin Nasopharyngeal Carcinoma,Chinese Journal of Oncology.2006,28(1).

    28.    Shusen Wang, Zhongzhen Guan, et al. The Significance of c-Fos, and Cyclin-D1Expression in Nasopharyngeal Carcinoma,Chinese Journalof Clinical Oncology,2005,32,(6)

    29.    Shusen Wang, Zhongzhen Guan, et al. In vivo Study of Epidermal Growth FactorReceptor-Selective Tyrosine Kinase Inhibitor Gefitinib on NasopharyngealCarcinoma. Chinese Journal of Cancer, 2004,23(11s).

    30.   Yanqun Xiang, Shusen Wang, et al Prognostic Value ofSurviving and Living in Nasopharyngeal Carcinoma, The Laryngoscope, 116(1).

    31.    Shusen Wang, Zhongzhen Guan, et al. Angiogenesis Modulator and Tumor. ChineseJournal of Medicine.2004, 4(1): 24-29.

    32.    Shusen Wang, Tongyu Lin, et al. Anti-Cancer Therapy Targeting EGFR. ChineseJournal of Cancer Palliative Medicine. 2003,2(4): 239-242.

    33.    Shusen Wang, Wenqi Jiang. Improving the Level of Clinical Study According toGood Clinical Practice. National Medical Journal of China.2003,83(3):179-180.

    34.    Shusen Wang , Ruilin Wang, et al. Study on the Purification of AngiogenesisInhibitor from Shark Cartilage and its Biological Characteristics. HenanJournal of Oncololgy.1999, 12(3): 179-181.

    35.    Shusen Wang, Lisong Tan, et al. A Study on the Method Using 1H11 EndothelialCells to Assay Angiogenesis Inhibitor. ACTA Academiae Medicinae Xuzhou. 1998,18 (3): 176-178.

    36.   Jinchuan Zhang, Shusen Wang, et al. Detecting TumorSpecific Growth Factor in Patients with Chemotherapy. Academiae MedicinaeXuzhou.2001, 21(2): 116-117.

    37.   Desheng liu, Shusen Wang et al. How to Improve theEffect and Safety of Three-Step Method of Analgesia. Chinese Journal ofClinical Oncology and Recovery.1999, 6 (5): 77-79. 

    Zhi-Ming Li
    Title Professor, Chief Physician
    Profile
    Dr. Li received his Bachelor Degree from Sun Yat-sen University in 1997 and his Doctoral Degree in Oncology from Sun Yat-sen University in 2002. Dr. Li research has been focused on the treatment and developing of solid tumor especially in lymphoma. At present he holds the position of secretary in Committee of Malignant Lymphoma, Chinese Anti-cancer Association and Committee of Chemotherapy, Guangdong Anti-cancer Association. He has been extensively involved in many several researches sponsored by Natural Science Foundation of China (NSFC), Chinese Postdoctoral Science Foundation and Guangdong Natural Science Foundation (GNSF) and edited "Cancer Biotherapy".
    Email
    Phone
    Research Interest(s)

    1. Mechanism of BAFF/NF-κB/Bcl-xL pathway to overcomeresistance to anti-CD20 monoclonal antibody in the combination withchemotherapy in DLBCL. NSFC. 2011-2013. Principal Investigator

    2. Experimental research of L-gossypol on chemotherapy innon-Hodgkin lymphoma. NSFC. 2005-2007. Principal Investigator

    3. Experimental research of RNA mediated by PLGAnanoparticles for mantle cell lymphoma. NSFC. 2004-2006.Second Investigator

    4. The anti-tumor function and mechanism for alkannin andderivatives. NSFC. 2003-2005. Second Investigator

    5. Developing molecular target of Cyclins/cdks and screening of anticancer drugs.NSFC. 2002-2004. Second Investigator

    6. Experimental research of selective tyrosine kinaseinhibitors of Her2/neu and its anti-cancer effect. NSFC. 2002-2004. FifthInvestigator

    7. Modeling VEGF/VEGFR and screening of anticancer drug.NSFC. 2001-2003. Fifth Investigator

    8. Mechanism of targeting mTOR mediatedautophagy-dependent senescence in lymphoma. GNSF. 2013-2015. SecondInvestigator

    9. The anti-tumor function and mechanism of L-gossypol onchemotherapy in non-Hodgkin lymphoma. GNSF.. 2005-2007. Principal Investigator

    10. Experimental research of selective tyrosine kinaseinhibitors of Her2/neu and its anti-cancer effect. GNSF. 2002-2003. FifthInvestigator

    11. The immune response of BAFF/TLR/MYD88 pathwaymediated autophagy-dependent regulation to anti-CD20 monoclonal antibody inDLBCL. Science and Technology Program of Guangzhou. 2013-2015. PrincipalInvestigator

    12. The single nucleotide polymorphisms of DPD andindividual therapy of 5-FU. Science and Technology Program of Guangzhou.2002-2005. Second Investigator

    13. The anti-tumor function and the mechanism ofautophagy-dependent senescence of targeting mTOR/bcl-xL/beclin 1 in thecombination with chemotherapy for patients of NHL. Foundation for DistinguishedYoung Talents in Higher Education of Sun Yat-sen University. 2011-2013.Principal Investigator

    14. Mechanism of BAFF/NF-κB/Bcl-xL pathway to overcomeresistance to anti-CD20 monoclonal antibody in the combination with chemotherapyin DLBCL. Foundation for Distinguished Young Talents in Sun Yat-sen UniversityCancer Center. 2011-2013. Principal Investigator

    15. Experimental research of RNA mediated by adenoviruswithout coenzyme for mantle cell lymphoma. Chinese Postdoctoral ScienceFoundation. 2005-2007. Principal Investigator

    16. Experimental research of L-gossypol of Bcl-xLinhibitor for  therapy of non-Hodgkinlymphoma Chinese Postdoctoral Science Foundation. 2005-2007. SecondInvestigator 
    Education Major: Medical Oncology especially in lymphoma and head & neck cancer
    Publications

    1. Li ZM, Zucca E, Ghielmini M. Open questions in the management of mantlecell lymphoma. Cancer Treat Rev. 2013 Oct;39(6):602-9.

    2. Li YJ, Jiang WQ, Huang JJ, Xia ZJ, HuangHQ, Li ZM. The Glasgow Prognostic Score (GPS) as a noveland significant predictor of extranodal natural killer/T-cell lymphoma, nasaltype.  Am JHematol. 2013 May;88(5):394-9.

    3. Li YJ, Li ZM, Xia XY, Huang HQ, Xia ZJ, Lin TY, Li S, Xia Y, Cai XY, Jiang WQ. Prognosticvalue of interim and posttherapy 18F-FDG PET/CT in patients with mature T-celland natural killer cell lymphomas. J NuclMed. 2013 Apr;54(4):507-15.

    4. Li ZM, Spagnuolo L, Mensah AA, Rinaldi A,Bhagat G, Zucca E, Doglioni C, Ferreri AJ, Ponzoni M, Bertoni F. Gains of CCND3 gene in ocular adnexal MALTlymphomas: an integrated analysis. Br J Haematol. 2013 Mar;160(5):719-22.

    5. Li ZM, Ghielmini M, Moccia AA.Managingnewly diagnosed follicular lymphoma: state of the art and future perspectives. Expert Rev Anticancer Ther. 2013 Mar;13(3):313-25.

    6. Wang Y, Li ZM, Huang JJ, Xia Y, Li H, LiYJ, Zhu YJ, Zhao W, Xia XY, Wei WX, Huang HQ, Lin TY, Jiang WQ.Three prognostic factors influence clinicaloutcomes of primary testicular lymphoma. Tumour Biol. 2013 Feb;34(1):55-63.

    7. Huang JJ, Zhu YJ, Xia Y, Zhao W, Lin TY,Jiang WQ, Huang HQ, Li ZM. A novel prognostic model for extranodalnatural killer/T-cell lymphoma. Med Oncol. 2012 Sep;29(3):2183-90.

    8. Li ZM, Zhu YJ, Sun J, Xia Y, Huang JJ, ZouBY, Lin TY, Huang HQ, Jiang WQ. Serum beta2-microglobin is a predictor ofprognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. Ann Hematol. 2012 Aug;91(8):1265-70.

    9. Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y,Huang HQ, Lin TY, Xia ZJ, Li S, Li ZM. Expression of BAFF and BAFF-R in follicularlymphoma: correlation with clinicopathologic characteristics and survivaloutcomes. PLoS One. 2012;7(12):e50936.

    10. Li ZM, Zhu YJ, Xia Y, Huang JJ, Jiang WQ. Clinical characteristics of the patients withHodgkin's lymphoma involving extranodal sites. Chin J Cancer. 2012 Jul;31(7):342-7.

    11. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y,Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ.Blood lymphocyte-to-monocyte ratio identifieshigh-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoSOne. 2012;7(7):e41658.

    12. Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W,Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ. High Ki-67 expression in diffuse large B-celllymphoma patients with non-germinal center subtype indicates limited survivalbenefit from R-CHOP therapy. Eur J Haematol. 2012 Jun;88(6):510-7.

    13. Zhu YJ, Sun YL, Xia Y, Jiang WQ, HuangJJ, Huang HQ, Lin TY, Guan ZZ, Li ZM. Clinical characteristics and prognosticfactors in Chinese patients with Hodgkin's lymphoma. Med Oncol. 2012 Jun;29(2):1127-33.

    14. Zhu YJ, Huang JJ, Xia Y, Zhao W, JiangWQ, Lin TY, Huang HQ, Li ZM. Primary mediastinal large B-cell lymphoma(PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. Int J Hematol. 2011 Aug;94(2):178-84.

    15. Huang JJ, Jiang WQ, Lin TY, Huang Y, XuRH, Huang HQ, Li ZM. Absolute lymphocyte count is a novel prognostic indicatorin extranodal natural killer/T-cell lymphoma, nasal type. AnnOncol. 2011 Jan;22(1):149-55. 

    16. Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH,Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY, Li ZM. Beclin 1 expression: predictorof prognosis in patients with extranodal natural killer T-cell lymphoma, nasaltype. Autophagy. 2010 Aug 24;6(6).

    17. Huang J, Jiang W, Xu R, Huang H, LvY, Xia Z, Sun X, Guang Z, Lin T, Li ZM. Primary gastric non-Hodgkin's lymphomain Chinese patients: clinical characteristics and prognostic factors. BMCCancer. 2010 Jul 6;10(1):358.

    Li Yu-Hong
    Title Chief Physician
    Profile
    Dr. Yu-Hong Li is Chief Physician in the Department of Medical Oncology at Sun Yat-sen University Cancer Center (SYUCC). She has extensive experience and expertise in the field of Medical Oncology, especially in gastrointestinal cancer (including colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, cholangio- carcinoma and gastrointestinal neuroendocrine tumor) and nasopharyngeal carcinoma. Dr. Li has been supported by The National Natural Science Foundation of China and other funds for her research and published over 100 peer-reviewed articles in many high impact journals such as Clin Cancer Res, Cancer, covering translational and clinical research topics. As a Member of the Good Clinical Practice in SYUCC, she has initiated or participated in many investigator initiated and SFDA approved clinical trails. She is also standing committee members of Guangdong province Anti-cancer association professional committee of colorectal cancer and esophageal cancer.
    Email liyh@sysucc.org.cn
    Phone 87343351
    Research Interest(s) Clinical and translational research for GI cancers and nasopharyngeal cancer.
    Education

    1994-1997 Sun Yat-sen University Cancer Center, M.S,Medical Oncology

    1986-1991  BenBu medical college, B.S, Clinical Medicine

    Postgraduate Training

    2011-Present  Chief Physician, Department of MedicalOncology, Cancer Center, Sun Yat-sen University, Guangzhou , Guangdong

    2009  Observer, Medical Oncology, Clinic, Rochester, Minnesota, USA

    2007  Observer, Medical Oncology, Paul Brouss HospitalFrance

    2005-2011  Associated Professor, Department of Medical Oncology, Cancer Center, Sun Yat-senUniversity, Guangzhou, Guangdong

    2000-2005  Attending Physician, Department of Medical Oncology, Cancer Center, Sun Yat-senUniversity, Guangzhou, Guangdong

    1997- 2000  Resident, Department of Medical Oncology, Cancer Center, Sun Yat-sen University,Guangzhou , Guangdong

    1991-1994 Resident, Internal Medicine, AnhuiProvincal Hospital, HeFei, Hanhui 2002-
    Publications

    1.       An X, Li YH (Corresponds).MET amplification is not rare and predictsunfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer afterchemotherapy. Cancer. 2014 Mar 1; 120(5):675.

    2.       An X, Li YH (Corresponds).Serum HER 2 extracellular domain level is correlated with tissue HER 2status in metastatic gastric orgastro-oesophageal junction adenocarcinoma.PLoS One. 2013 May 14;8(5):e63458.

    3.       Chen C, Li YH (Corresponds). Polymorphisms in ERCC1 C8092A predict progression-free survival inmetastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-basedchemotherapy. Cancer Chemother Pharmacol. 2013 Aug; 72(2):315.

    4.       Chen C, Li YH (Corresponds).Tripletcombination with paclitaxel, cisplatin and 5-FU is effective in metastaticand/or recurrent nasopharyngeal carcinoma.Cancer Chemother Pharmacol.2013Feb; 71(2):371.

    5.       Chen C, Li YH (Corresponds).Salvagegemcitabine- vinorelbine chemotherapy in patients with metastaticnasopharyngeal carcinoma pretreated with platinum- based chemotherapy. Oral Oncol.2012 Nov; 48(11):1146.

    6.       Li YH, Wang F,et al. EGFR FISH Pattern of Chromosome 7Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic ColorectalCancer Patients. Clin Cancer Res.2011; 15; 17(2):382.

    7.       An X, Li YH (Corresponds).PlasmaEpstein-Barr virus DNA level strongly predicts survival in metastatic/recurrentnasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;15; 117(16):3750.

    8.       An X, Li YH (Corresponds).Elevatedneutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngealcarcinoma. Tumor Biol.2011; 32(2):317.

    9.       Wang FH, Li YH (Corresponds).Phase IIstudy of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin asfirst-line chemotherapy in patients with advanced gastric cancer. Am J ClinOncol. 2011; 34(4):401.

    10.   Yu Hong Li, HuiYan Luo, et al. Phase II study of capecitabine plusoxaliplatin(XELOX) as first-line treatment and followed by maintenance ofcapecitabine in patients with metastatic colorectal cancer. J Cancer Res ClinOncol.2010; 136(4):503.

    11.   An X, Ding PR, Li YH (Corresponds).Carcinoembryonic antigen surge in metastatic colorectal cancer patientsresponding to irinotecan combination chemotherapy. Biomarkers.2010; 15(3):243.

    12.   Li YH, Hu CF, etal. Elevated Expressions of Survivin andVEGF Protein are Strong Independent Predictors of Survival in Advanced NasopharyngealCarcinoma. J Transl Med. 2008; 3; 6(1):1.

    13.   Li YH, Wang FH,et al. Phase II study of capecitabine andcisplatin combination as first-line chemotherapy in Chinese patients withmetastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008; 62(3):539.

    14.   He YF, Li YH(Corresponds) et al. Theeffectiveness of lamivudine in preventing hepatitis B viral reactivation inrituximab-containing regimen for lymphoma. Ann Hematol. 2008; 87(6):481.

    15.   Luo HY, Li YH,et al. Efficacy of CPT-11 combined 5-FU/CF(FOLFIRI) regimen on advanced colorectal cancer. Ai Zheng. 2007; 26(8):905.

    16.   Li YH, He YF, et al. Lamivudineprophylaxis reduces the incidence and severity of hepatitis in hepatitis Bvirus carriers who receive chemotherapy for lymphoma. Cancer. 2006, 15;106(6):1320-1325.

    17.   He YF, Li YH (Correspondence), et al.Prognostic analysis of 220 colorectal cancer patients with synchronous livermetastases. Ai Zheng. 2006; 25(9):1153.

    18.   Wang FH, Li YH, et al. PhaseI Clinical Trial of Intravenous Recombinant Human Lymphotoxin-α Derivative. Aizheng.2006; 26(4):501.

    19.   Xiang XJ,He YJ ,Li YH .Clinical Significance of SurvivinExpression in Peripheral T-cell Lymphoma. Ai zheng.2006; 25(6):758.

    20.   Li YH, He YF, et al. Clinical analysisof liver damage of 116 malignant lymphoma patients with chronic HBV infectionafter cytotoxic chemotherapy. Ai zheng.2005, 24(12):1507.

    21.   Li YH, Shao JYet al. The clinical significance of MMP-9CD44v6 protein expression in nasopharyngeal carcinoma. Ai zheng. 2004; 31(20):1153.

    22.   Li YH, Shao JY, etal. Clinical Significance of Quantitative Analysis of plasma Epstein-Barr virusDNA Concentration in nasopharyngeal carcinoma. Chinese J of Clinical Oncology. 2004; 31(8)421.

    23.   Li YH, Shao JY, et al.Clinical significanceof quantitative analysis of serum VEGF, CD44s, and MMP-3 protein in nasopharyngealcarcinoma. Ai zheng. 2004; 23(9):1060.

    24.   He YF, Li YH, Huang HQ,et al.Prognosis analysis of 53 cases with primary intestinal Non- Hodgkin's lymphoma.Ai zheng. 2005, 24(4):475.

    25.   Shao JY, Li YH, et al. Comparison ofplasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/viruscapsid antigen antibody titers in patients with nasopharyngeal carcinoma.Cancer. 2004; 15; 100(6):1162.

    26.   Shao JY, Li YH, et al. High frequencyof common deletion (4981 bp) in mitochondrial DNA in nasopharyngeal carcinomaand its correlation with patient age and clinical stages. Cancer Biol Ther.2004; 3(12):1270.

    27.   Li YH, Shao JY, et al. Quantitativeanalysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrenceand metastasis in nasopharyngeal carcinoma patients after radiotherapy. Aizheng. 2003; 22(6):645.

    28.   Li YH, Jiang WQ, et al. Clinicalanalysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma. Ai zheng.2003; 22(4):401.

    29.   Shao JY, Li YH, et al. High frequencyloss of heterozygosity on the long arms of chromosomes 13 and 14 innasopharyngeal carcinoma in Southern China. Chinese Medical Journal. 2002;115(4):571.

    30.   Shao JY, Li YH, et al. Deletion ofchromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 andp15/MTS2 gene protein in hepatocellular carcinomas. Chinese Medical Journal,2000; 113(9):817.  

    31.   Zhang DS,Din Y, Li YH, et al. PredictiveSignificance of Serum 90K/Mac-2BP on Chemotherapy Response in Non-Hodgkin'sLymphoma. Ai zheng. 2005; 24(8):1006.

    32.   Xiang XJ,He YJ ,Li YH .PrognosisAnalysis of 53 Cases with Primary Intestinal Non- Hodgkin's Lymphoma. Ai zheng.2004; 23(4):443.

    33.   Shao JY, Gao HY, Li YH et al.Quantitative detection of common deletion of mitochondrial DNA inhepatocellular carcinoma and hepatocellular nodular hyperplasia. World JGastroenterol. 2004; 10(11):1560.

    34.   Li YH, Jiang WQ, et al. Preliminarystudy on DHAP regimen for patients with relapsed and refractory non-Hodgkin'slymphoma: Ai zheng. 2002; 21(8):900.

    35.   Huang HQ, Zhou ZM, Li YH, et al. Preliminaryresults of Ifosfamide and Doxorubicin regimen in treatmentof patients with recurrentand metastatic nasopharyngeal carcinoma. Ai zheng.2002, 21(4):409.

    36.   Li YH, Rao HL,et al. Anaplasticlarge cell lymphoma—review and 20 cases report. Ai zheng. 2000; 19(9):914.

    37.   Li YH, He YJ, et al. Clinical trialof 5FU/CF and carboplatin combination chemotherapy in patients with advancednasopharyngeal carcinoma (NPC). Ai zheng.1999; 18(3):295.

    38.   Li YH, Xu RH,et al. Apilot study of 5-FU circadian pharmacokinetics in patients with nasopharyngealcarcinoma .Ai zheng.1999;18(6):694.

    39.   Guan zz,Chen RQ,Xu GC, Li YH, et al. Gemcitabinein the treatment of advanced nonsmallcell lung cancer. Ai zheng.1999; 18(3);241.

    Huang HQ, Li YH, He YJ.Preliminary result of DDP, 5 Fu and High dose Leucovorin (HDCF) Plus Interferon(INF) for the treatment of Advanced or Reccurent Nasopharyngeal Carcinoma(NPC). Ai zheng.1998; 17(6):450
    Ying Liang
    Title Associate Professor
    Profile

    Dr. Ying Liang is an Associate professor of Department of Medical Oncology, Sun Yat-sen University Cancer Center. Dr. Liang obtained her MD and PhD degree at Sun Yat-sen University of Medical Sciences in 2000 and 2009, respectively. She has been working in Sun Yat-sen University Cancer Center since 2002. From 2013 to 2014, she studied at Stanford Cancer Institute, Stanford University School of Medicine. Dr. Liang’s major research interests are medical treatment and research on thoracic malignancies (non-small cell lung cancer, small cell lung cancer, thymic malignancy, malignant pleural mesothelioma, esophageal cancer, etc.), lymphoepithelioma-like carcinoma and nasopharyngeal carcinoma. Dr. Liang has authored or coauthored more than 40 peer-reviewed articles in scientific journals including Cancer, British Journal of Caner, Annals of Surgical Oncology, Lung Cancer and Clinical Lung Cancer, ect. She has participated in many international randomized control studies, SFDA approved clinical trials, investigator initiated trials and phase I trials. Dr. Liang is a member of International Association for the Study of Lung Cancer (IASLC), International Thymic Malignancies Interest Group (ITMIG) Dr. Liang serves on the editorial boards of Translational Lung Cancer Research, and the invited reviewer of Journal of Thoracic Oncology, Lung Cancer, Journal of Thoracic Disease, BMC Case Report.


    Email
    Phone
    Research Interest(s)
    Education
    Publications
    Liu Yushan
    Title Associate chief nurse practitioner
    Profile
    Ms. Liu Yushan currently serves as associate chief member of Internal Medicine Specialized Committee of Chinese Nursing Association and Director of Nursing of the forth district of Chemotherapy and Bone Marrow Transplantation Room. She has been engaged in chemotherapy nursing at the Chemotherapy, including chemotherapy nursing for gastroenteric tumor, head and neck cancer, lung cancer, soft tissue cancer, breast cancer, multiple myeloma. She has abundant clinical experiences in chemotherapy nursing for lymphoma and nursing for marrow transplantation. Ms Liu has been participating in formulation of nursing routines for chemotherapy and marrow transplantation of the Hospital, undertaking training for nursing students and nurses seeking further education, and participating in nursing for clinical trial of multiple anticancer drugs. She has also obtained Good Clinical Practice (GCP) Certificate and Peripheral Inserted Central Catheter (PICC) Certificate, and published several papers on nursing:
     
    1. Application of peripheral venous catheter in hematopoietic stem cell transplantation
    2. Nursing for patient with advanced colorectal cancer treated with new anticancer drug Campto
    3. Study on disinfection methods of laminar flow for hematopoietic stem cell transplantation
    4. Nursing risks and precautionary measures for clinical trial for new anticancer drugs
    5. Health education for patients undergoing autologous peripheral blood stem cell transplantation
    Email liuysh@sysucc.org.cn
    Phone 87343355
    Research Interest(s)
    Education
    07/1983-07/1986 Graduated from Nursing major, former Affiliated Nursing School of Sun Yat-sen University of Medical Sciences1999-04/2011 Participated in Self-taught Higher Education Examination for nursing and obtained graduation certificate of junior college
    Publications
    Cai Qing-Qing
    Title Associate Professor, tutor of Master’s Degree students
    Profile
    Dr. Qing-Qing Cai is an associate professor of medical Oncology. Dr. Cai obtained her Bachelor in Clinical Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Oncology in 1998 and 2009, respectively. In 2013-2014, she studied as a visiting scholar at department of Lymphoma and Myeloma of the University of Texas MD Anderson Cancer Center.
     
    Dr. Cai has clinical and research interests in lymphoma, head and neck cancers (including nasopharynx cancer), gastrointestinal cancers and soft tissue sarcoma. She also is focused on autologous stem-cell transplants for malignancies. Dr. Cai has undertaken a number of research projects, the research funds of recent years are up to 150,000 RMB. She has published in several journals, including British Journal of Cancer, International Journal of Cancer, PLoS One, and so on. The cumulative impact factor of the papers published in recent years is more than 50 points.
     
    Dr. Cai was recognized for her clinical achievements with the Outstanding Physician Award of Cancer Center, Sun Yat-sen University in 2006, 2008-2010. Her efforts also have been recognized with Cancer Center, Sun Yat-sen University for Anti-cancer Science Award of Mr Deng in 2009. She also was a Young Talents of Cancer Center, Sun Yat-sen University in 2010 and Young Talents of Sun Yat-sen University in 2011.Dr. Cai is currently the vice chairman of Younger Committee of Chinese Society of Oncology, the chairman of Lymphoma Committee of the Anti-cancer Society of Guangdong Province, and the chairman of Lymphoma Committee of the Anti-cancer Society of Guangzhou.
    Email caiqq@sysucc.org.cn
    Phone +86-20-87342731
    Research Interest(s)

    Chemotherapyfor lymphoma, head and neck cancers (including nasopharynx cancer), gastrointestinal cancers and soft tissue sarcoma;Targeted Therapy; Autologous Stem-Cell Transplants for Malignancies.

    Research projects as follows:

      1)2013: Supported by National Natural Science Foundation of China (#813728830):CyclinE2-3’ UTR promotes nasopharyngeal carcinoma metastasis throughcompetitively binding of miR-30e to up-regulate Notch1 expression. PrincipleInvestigator, 2014-2017, RMB: 800,000

      2)2011: Supported by Young Talents Project of Sun Yat-sen University: Study ofthe initiating and developing mechanism of extranodal nasal-type NK/T-celllymphoma which are promoted by lncRNA MALAT1. Principle Investigator, 2012-2015, RMB:150,000

      3)2011: Supported by Science and Technology Planning Project of GuangdongProvince, China (grant number: 2011B031800222): Study of the significance andfunction of miR-374b in T-Non Hodgkin's lymphoma.  Principle Investigator, 2012-2014. RMB:30,000

      4)2010: Supported by National Natural Science Foundation of China (#81001052):Study of miR-374b induce apoptosis of T-Non Hodgkin's lymphoma by targetingAKT. Principle Investigator, 2011-2013, RMB:200,000   

      5)2010: Supported by Young Talents Project of Sun Yat-sen University CancerCenter: Study of miR-374b induce apoptosis of T-Non Hodgkin's lymphoma bytargeting AKT. Principle Investigator, 2011-2015, RMB:250,000

      6)2008: Guangdong Province Natural Scientific Grant (8151008901000043). Study of13-Methyltetradecanoic acid exhibits anti-tumor activity on T cell lymphomas bydown-regulation of p-AKT/AKT pathway. Principle Investigator, 2009-2011, RMB:50,000

      7)2007: Supported by Science and Technology Planning Project of GuangdongProvince, China (grant number: 0711220600052). Detection and clinicalsignificance of circulating tumor cells in the peripheral blood ofnasopharyngeal cancer patients using modified IME-ICC method.  Principle Investigator, 2008-2010, RMB:30,000

      8)2006: Supported by Medical Scientific Research Foundation of GuangdongProvince, China (#B2005052). Detection circulating tumor cells in theperipheral blood of nasopharyngeal cancer patients using immunomagneticenrichment and fluorescent immunocytochemistry.  Principle Investigator, 2007-2009, RMB:5,000

     

    Education

    Qualifications

    September 2006 –July 2009, Sun Yat-sen university, Guangzhou, China. Ph.D. for MedicalOncology.

    September 2001-July 2004, Sun Yat-sen University, Guangzhou, China. M.S. for Medical Oncology.

    September 1993–July 1998, Sun Yat-sen University, Guangzhou, China. B.S. for ClinicalMedicine.

    Work experience

    April 2013- April2014, Visiting Scholar. Department of Lymphoma and Myeloma, The University ofTexas MD Anderson Cancer Center.

    December 2009- present,Associate professor. Lymphoma and HSCT Transplant Section, Department ofMedical Oncology, Cancer Center, Sun Yat-sen University.

    December 2005-December 2009, Attending Physician, Department of Medical Oncology, CancerCenter, Sun Yat-sen University.

    August 2004 -December 2005, Resident, Department of Medical Oncology, Cancer Center, SunYat-sen University.

    2002-2003, ResearchAssociate, Keck School of Medicine, University of Southern California       

    July 1998 - August 2001, Resident, Medicaloncology department, the Sixth People’s Hospital of Guangzhou, the AffiliatedHospital of Cancer Center, Sun Yat-sen University.

    Publications

    1)   Cai Q, Chen Y, Zou D, Zhang L, BadilloM, Zhou S, Lopez E, Jiang W, Huang H, Lin T, Romaguera J, Wang M. Clinicaloutcomes of a novel combination of lenalidomide and rituximab followed by stemcell transplantation for relapsed/refractory aggressive B-cell non-hodgkinlymphoma. Oncotarget. Received: June 02, 2014 Accepted: July 24, 2014 Publishedonline: July 25, 2014.

    2)   Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M.Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol.2013 Dec 28. [Epub ahead of print]

    3)   Cai Q, Luo X, Zhang G, Huang H, Huang H, Lin T,Jiang W, Xia Z, Young KH. 1.          Newprognostic model for extranodal natural killer/T cell lymphoma, nasal type. AnnHematol. 2014 Apr 30. [Epub ahead of print]

    4)   Luo XL, He W, Huang H, Chen QY, Liang Y, Mai HQ, Huang HQ, Cai Q (corresponding author). Design ofa prognostic score model for nasopharyngeal carcinoma. Head Neck. 2014 Mar 6.doi: 10.1002/hed.23642. [Epub ahead of print].

    5)   Cai Q, Huang H, Qian D, Chen K, Luo J, Tian Y, LinT, LinT.  13-Methyltetradecanoic AcidExhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo byDown-Regulating p-AKT and Activating Caspase-3.PLoS One. 2013 Jun7;8(6):e65308.

    6)   Cai Q,Luo X, Liang Y, Rao H, Fang X, Jiang W, Lin T, Lin T, Huang H. Fasting bloodglucose is a novel prognostic indicator for extranodal natural killer/T-celllymphoma, nasal type. British Journal of Cancer. 2013,108(2):380-386.

    7)   Huang F, Zhang K, Chen J, Cai Q, Liu X, Wang T, Lv Z, Wang J, Huang H. Elevation of carbohydrate antigen 125 inchronic heart failure may be caused by mechanical extension of mesothelialcells from serous cavity effusion. Clin Biochem. 2013 Nov;46(16-17):1694-700.doi: 10.1016/j.clinbiochem.2013.09.008. Epub 2013 Sep 21.

    8)   He W, Cai Q(co-first author),Sun F, Zhong G, Wang P, Liu H, Luo J, Yu H, Huang J, Lin T. linc-UBC1physically associates with polycomb repressive complex 2 (PRC2) and acts as anegative prognostic factor for lymph node metastasis and survival in bladdercancer. Biochim Biophys Acta. 2013 May 18.

    9)   Fan X, Chen X, Deng W, Zhong G, CaiQ (co-corresponding author), Lin T. Up-regulated microRNA-143 in cancerstem cells differentiation promotes prostate cancer cells metastasis bymodulating FNDC3B expression. BMC Cancer. 2013 Feb 5;13:61.(IF: 3.011)

    10)  Cai Q, Deng H, Xie D, Lin T, Lin T. Phosphorylated AKT Protein IsOverexpressed in Human Peripheral T-cell Lymphomas and Predicts DecreasedPatient Survival. Clin Lymphoma Myeloma Leuk. 2012; 12(2):106-12.

    11)  Luo J, Cai Q, Wang W, HuangH, Zeng H, He W, Deng W, Yu H, Chan E, Ng CF, Huang J, Lin T.A MicroRNA-7 Binding SitePolymorphism in HOXB5 Leads to Differential Gene Expression in Bladder Cancer. PLoS One. 2012;7(6):e40127.

    12)  Huang H, Lin Z, Lin X, Cai Q, Xia Z, Jiang W. Long-term outcomes ofpatients with newly diagnosed extranodal natural killer/T-cell lymphoma treatedby etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicinregimen: a single-institution experience. Leuk Lymphoma. 2011;52(6):1041-8.

    13)  Lin T, Yin X, Cai Q(co-first author), Fan X, Xu K, Huang L, Luo J, Zheng J, HuangJ. 13-Methyltetradecanoicacid induces mitochondrial-mediated apoptosis in human bladder cancer cells.Urol Oncol. 2012;30(3):339-45.

    14)  Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J, Lin T. MicroRNA-125b suppresses thedevelopment of bladder cancer by targeting E2F3. Int J Cancer.2011;128(8):1758-69.

    15)  Huang H, Cai Q(co-first author) , Lin T, Lin X,Liu Y, Gao Y, Peng R. Lamivudinefor the prevention of hepatitis B virus reactivation after high-dosechemotherapy and autologous hematopoietic stem cell transplantation forpatients with advanced or relapsed non-Hodgkin's lymphoma single institutionexperience. Expert Opin Pharmacother. 2009;10(15):2399-406.

    16)  Cai Q, Huang H, Sun X, XiaZ, Li Y, Lin X, Guo Y. Efficacyand safety of transdermal fentanyl for treatment of oral mucositis pain causedby chemotherapy. Expert Opin Pharmacother. 2008; 9(18):3137-44.

    Peng Rou-Jun
    Title Associate Professor
    Profile
    Dr. Rou-Jun Peng is associated professor of Department of Medical Oncology, Sun Yat-sen University Cancer Center. Dr. Peng obtained her Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University, P. R. China in 2000 and 2011, respectively. She had the collaborateive PhD student training at Karolinska Institutet, Sweden from Sep 2008 to Sep 2010, which provided her with great opportunities to explore the fields of lymphoma pathologenesis. She joined the Department of Medical Oncology at Sun Yat-sen University Cancer Center (SYSUCC) as a associated Professor in Dec 2013. Dr. Peng has published more than 20 research papers. Now Dr. Peng’s clinical specialty is the treatment of breast cancer, and the research interest is in the field of breast caner biology.
    Email pengrj@sysucc.org.cn
    Phone 86 20 87343794
    Research Interest(s)
    Dr. Rou-Jun Peng is interested in the mechanism of resistance to Traustuzumab in ErbB2 overexpression breast cancer, the molecular biology of triple-negative breast cancer, the mechanism of circulating tumor cell to metastasis of breast cancer. She specialized in the treatment of breast cancer.
    Education

    1995-2000:Medical College, Sun Yat-Sen University. Awarded a Bachelor degree of Medicine.      

    2003-2007: Sun Yat-Sen University.Awarded a Master degree of Clinical Oncology.                          

    2007-2011: Sun Yat-SenUniversity. Awarded a PhD degree of Oncology.                                  

    2008-2010: Karolinska Institutet,Sweden. Collaborative training for PhD student.

    Publications

    1. de Miranda NF, Peng R, Georgiou K, Wu C,Falk Sörqvist E, Berglund M, Chen L, Gao Z, Lagerstedt K, Lisboa S, Roos F, vanWezel T, Teixeira MR, Rosenquist R, Sundström C, Enblad G, Nilsson M, Zeng Y,Kipling D, Pan-Hammarström Q. 2013. DNA repair genes are selectively mutated indiffuse large B cell lymphomas. J Exp Med 210: 1729-42. [co-first author].                                           

    2. DuL, Peng RJ, Bjorkman A, Filipe de Miranda N, Rosner C, Kotnis A, Berglund M,Liu C, Rosenquist R, Enblad G, Sundstrom C, Hojjat-Farsangi M, Rabbani H,Teixeira MR, Revy P, Durandy A, Zeng Y, Gennery AR, de Villartay JP,Pan-Hammarstrom Q. 2012. Cernunnos influences human immunoglobulin class switchrecombination and may be associated with B cell lymphomagenesis. J Exp Med 209:291-305. [co-first author].                                

    3. Peng RJ, Huang ZF, Zhang YL, Yuan ZY, XiaY, Jiang WQ, Zeng YX, Li J. 2011. Circulating and tumor-infiltrating Foxp3(+)regulatory T cell subset in Chinese patients with extranodal NK/T celllymphoma. Int J Biol Sci 7: 1027-36.                                                                   

    4. Peng RJ, Wang S, Shi Y, LiuD, Teng X, Qin T, Zeng Y, Yuan Z. 2011. Patients 35 years old or younger withoperable breast cancer are more at risk for relapse and survival: aretrospective matched case-control study. Breast 20: 568-73.                                                                   

    5. Xia Q, Cai Y, Peng RJ, Wu G, Shi Y, JiangW. 2014. The CDK1 inhibitor RO3306 improves the response of BRCA-proficientbreast cancer cells to PARP inhibition. Int J Onco 44:735-44.                                     

    6. Tan DE, Foo JN, Bei JX, Chang J, Peng RJ, Zheng X, Wei L, HuangY, Lim WY, Li J, Cui Q, Chew SH, Ebstein RP, Kuperan P, Lim ST, Tao M, Tan SH,Wong A, Wong GC, Tan SY, Ng SB, Zeng YX, Khor CC, Lin D, Seow AL, Jia WH, LiuJ. 2013. Genome-wide association study of B cell non-Hodgkin lymphomaidentifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet45:804-7.                                                                         

    7. Qin T, Yuan Z, Peng RJ, Bai B, Shi Y, TengX, Liu D, Wang S. 2013. HER2-positive breast cancer patients receivingtrastuzumab treatment obtain prognosis comparable with that of HER2-negativebreast cancer patients. Onco Targets Ther 6:341-7.                                                                                             

    8. Xue C, Wang X, Peng RJ, Shi Y, Qin T,Liu D, Teng X, Wang S, Zhang L, Yuan Z. 2012. Distribution, clinicopathologicfeatures and survival of breast cancer subtypes in Southern China. Cancer Sci103: 1679-83.                         

    9. Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, An X, Cao Y, TanYT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. 2012. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer. J Cancer Res Clin Oncol 138: 705-14.                                                                             

    10.Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, AnX, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. 2012. Comparison of overallsurvival between the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breastcancer. Med Oncol 29: 39-47.                                     

    11. Wang X, Wang SS, Peng RJ, Qin T, Shi YX, Teng XY,Liu DG, Chen WQ, Yuan ZY. 2012. Interaction of coping styles and psychologicalstress on anxious and depressive symptoms in chinese breast cancer patients.Asian Pac J Cancer Prev 13: 1645-9.                                                                                              

    12. Liu DG, Wang SS, Peng RJ, Qin T, Shi YX, TengXY, Wang X, Chen WQ, Yuan ZY. 2012. Interaction of social support andpsychological stress on anxiety and depressive symptoms in breast cancerpatients. Asian Pac J Cancer Prev 12: 2523-9.                                                                   

    13. Liu D, He J, Yuan Z, Wang S, Peng RJ, Shi Y,Teng X, Qin T. 2012. EGFR expression correlates with decreased disease-freesurvival in triple-negative breast cancer: a retrospective analysis based on atissue microarray. Med Oncol 29: 401-5.                                                                                              

    14. He J, Peng RJ, Yuan Z, Wang S, Peng J, Lin G,Jiang X, Qin T. 2012. Prognostic value of androgen receptor expression inoperable triple-negative breast cancer: a retrospective analysis based on atissue microarray. Med Oncol 29: 406-10.                                                             

    15. Liu P, Fang X, Feng Z, Guo YM, Peng RJ, LiuT, Huang Z, Feng Y, Sun X, Xiong Z, Guo X, Pang SS, Wang B, Lv X, Feng FT, LiDJ, Chen LZ, Feng QS, Huang WL, Zeng MS, Bei JX, Zhang Y, Zeng YX. 2011. Directsequencing and characterization of a clinical isolate of Epstein-Barr virusfrom nasopharyngeal carcinoma tissue by using next-generation sequencingtechnology. J Virol 85: 11291-9.                                                                         

    16. Gu AD, Mo HY, Xie YB, Peng RJ, Bei JX, Peng J,Li MY, Chen LZ, Feng QS, Jia WH, Zeng YX. 2008. Evaluation of a multianalyteprofiling assay and an enzyme-linked immunosorbent assay for serologicalexamination of Epstein-Barr virus-specific antibody responses in diagnosis ofnasopharyngeal carcinoma. Clin Vaccine Immunol 15: 1684-8.                                                                          

    17. Peng RJ, Sun XF, Xiang XJ, Zhen ZJ, Ling JY,Tong GL, Xia Y, Xu GC, Jiang WQ. 2009. [Efficacy and survival of 92 cases ofEwing's sarcoma family of tumor initially treated with multidisciplinarytherapy]. Ai Zheng 28: 1304-9.                                                                                                 

    18. Shi YX, Peng RJ, Lin SX, Wu QL, Lin TY, SunXF, Huang HQ, Xia ZJ, Li YH, Xu RH, Liu DG, Guan ZZ, Jiang WQ. 2007. [A survivalof 103 cases of T-cell non-Hodgkin lymphoma]. Zhonghua Nei Ke Za Zhi 46:1000-2.                                                                                

    19. Shi YX, Han WJ, Peng RJ., etal. Screening of RNA Intervening Targets of foxp3 Gene with FLAG Fusion Peptideand Lentivirus Vector. Journal of Sun Yat-Sen University (Medical Sciences).2007,28(6):641-644.                        

    20. Peng RJ, Q.M. Dong, Y.X. Shi, Y. Cao,Z.M. Zhou, Z.Y. Yuan, S. Li, H. Liao, W.Q. Jiang. 2006. Correlative analysisbetween serum dihydropyrimidine dehydrogenase, activity, concentration of5-fluorouracil and adverse events in the treatment of advanced gastric cancerpatients. Ai Zheng 25:1039-1043.                                                    

    21. Liu, D.G., R.J. Peng, F.Y. Feng, X.H.Hu, G.D. Tang, J.P. Xiong, H.Y. Zhao, Y. Guo, and Z.Z. Guan. 2006. Randomizedcontrolled trial of two kinds of home-produced docetaxel in China for advancedbreast cancer. Ai Zheng 25:1557-1560.                                                                 

    22. Li, Z.G., Y.X. Shi, R.J. Peng, M.Q. Zhu, andY.Y. Wan. 2006. Blocking enhancive effect of vascular endothelial growth factoron proliferation of rhabdomyosarcoma cell line RH4 by avastin. Ai Zheng25:718-722.                                                                             

    23. Cao Y, Li HL, R.J. Peng, et al. Design stageI clinical trial of target, non-cytotoxic agents. Journal of Sun Yat-SenUniversity (Medical Sciences). 2006,28(4s): 44-46.

    Yuan Zhong-Yu
    Title Associate Professor
    Profile
    Dr. Zhong-Yu Yuan is Associate Professor of Medical Oncology of Sun Yat-sen University Cancer Center. Dr. Yuan obtained his doctor's degree in Medicine at Sun Yat-sen University, P. R. China in 2003. His primary interest is breast cancer treatment, particularly in the treatment and research on triple negative breast cancer. Dr. Yuan clinical focus is on development of new approaches for prevention and treatment of breast cancer. Dr.Yuan has published more than 20 peer-reviewed journal articles and has presented her work at St.Gallen national meetings.
    Email yuanzhy@sysucc.org.cn
    Phone 86-20-87342496
    Research Interest(s) Breast Cancer
    Education
    Bachelor and Master at Anhui Medical University in 1989 and 2000, respectively. Doctor at Sun Yat-sen University in 2003.
    Publications

    1. He JH, Luo RZ, Cai MY, Li M, Lu JB, Yuan ZY:Decreased expression of light chain 3 (LC3) increased the risk of distantmetastasis in triple-negative breast cancer. Medical oncology 2013,30(1):468.

    2. Xu J, Wu X, Zhou WH, Liu AW, Wu JB, Deng JY, Yue CF, Yang SB, WangJ, Yuan ZY et al: Aurora-a identifies early recurrence and poor prognosis andpromises a potential therapeutic target in triple negative breast cancer. PloSone 2013, 8(2):e56919.

    3. Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X, Liu D,Wang S: HER2-positive breast cancer patients receiving trastuzumab treatmentobtain prognosis comparable with that of HER2-negative breast cancer patients.OncoTargets and therapy 2013, 6:341-347.

    4. Qin T, Yuan ZY, Peng RJ, Zeng YD,Shi YX, Teng XY, Liu DG, Bai B, Wang SS: Efficacy and tolerability oftoremifene and tamoxifen therapy in premenopausal patients with operable breastcancer: a retrospective analysis. Current oncology 2013, 20(4):196-204.

    5. LuoRZ, Yuan ZY, Li M, Xi SY, Fu J, He J: Accumulation of p62 is associated withpoor prognosis in patients with triple-negative breast cancer. OncoTargets andtherapy 2013, 6:883-888.

    6. Xue C, Wang X, Peng R, Shi Y, Qin T, Liu D, Teng X,Wang S, Zhang L, Yuan Z: Distribution, clinicopathologic features and survivalof breast cancer subtypes in Southern China. Cancer science 2012,103(9):1679-1687.

    7. Wang X, Wang SS, Peng RJ, Qin T, Shi YX, Teng XY, Liu DG,Chen WQ, Yuan ZY: Interaction of coping styles and psychological stress onanxious and depressive symptoms in Chinese breast cancer patients. AsianPacific journal of cancer prevention : APJCP 2012, 13(4):1645-1649.

    8. He J,Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T: Prognostic value ofandrogen receptor expression in operable triple-negative breast cancer: aretrospective analysis based on a tissue microarray. Medical oncology 2012,29(2):406-410.

    9. Liu D, He J, Yuan Z, Wang S, Peng R, Shi Y, Teng X, Qin T:EGFR expression correlates with decreased disease-free survival intriple-negative breast cancer: a retrospective analysis based on a tissuemicroarray. Medical oncology 2012, 29(2):401-405.

    10. Wang S, Shi Y, Yuan Z,Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G et al: Classical CMFregimen as adjuvant chemotherapy for triple-negative breast cancer may be moreeffective compared with anthracycline or taxane-based regimens. Medicaloncology 2012, 29(2):547-553.

    11. Wang F, He W, Qiu H, Wang X, Guo G, Chen X,Rong Y, Zhou F, Yin C, Yuan Z et al: Lymph Node Ratio and pN Staging ShowDifferent Superiority As Prognostic Predictors Depending on the Number of LymphNodes Dissected in Chinese Patients With Luminal A Breast Cancer. Clinicalbreast cancer 2012, 12(6):404-411.

    12. Zou Z, Yuan Z, Zhang Q, Long Z, Chen J,Tang Z, Zhu Y, Chen S, Xu J, Yan M et al: Aurora kinase A inhibition-inducedautophagy triggers drug resistance in breast cancer cells. Autophagy 2012,8(12):1798-1810.

    13. Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, An X, Cao Y, JinY, Cai XY, Sun YL et al: Comparison of overall survival between the early useand delayed use of Trastuzumab therapy groups: a retrospective analysis of 128patients with HER-2-positive advanced breast cancer. Medical oncology 2012,29(1):39-47.

    14. Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, An X, Cao Y, Tan YT,Jin Y, Cai XY et al: Comparison of clinicopathological characteristics andprognoses between bilateral and unilateral breast cancer. Journal of cancerresearch and clinical oncology 2012, 138(4):705-714.

    15. Liu DG, Wang SS, PengRJ, Qin T, Shi YX, Teng XY, Wang X, Chen WQ, Yuan ZY: Interaction of socialsupport and psychological stress on anxiety and depressive symptoms in breastcancer patients. Asian Pacific journal of cancer prevention : APJCP 2011,12(10):2523-2529.

    16. Peng R, Wang S, Shi Y, Liu D, Teng X, Qin T, Zeng Y, YuanZ: Patients 35 years old or younger with operable breast cancer are more atrisk for relapse and survival: a retrospective matched case-control study.Breast 2011, 20(6):568-573.

    17. Peng RJ, Huang ZF, Zhang YL, Yuan ZY, Xia Y,Jiang WQ, Zeng YX, Li J: Circulating and tumor-infiltrating Foxp3(+) regulatoryT cell subset in Chinese patients with extranodal NK/T cell lymphoma.International journal of biological sciences 2011, 7(7):1027-1036.

    18. Qiu MZ,Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH: Impact ofpretreatment hematologic profile on survival of colorectal cancer patients.Tumour biology : the journal of the International Society for OncodevelopmentalBiology and Medicine 2010, 31(4):255-260.

    19. Bai B, Yuan ZY, Liu DG, Teng XY,Wang SS: Clinical features and survival analysis of different subtypes ofpatients with breast cancer brain metastases. Chinese journal of cancer 2010,29(4):413-419.

    20. Zhou FF, Xia LP, Guo GF, Wang X, Yuan ZY, Zhang B, Wang F:Changes in therapeutic strategies in Chinese male patients with breast cancer:40 years of experience in a single institute. Breast 2010, 19(6):450-455.

    21.Xia LP, Zhou FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B: Chinese femalebreast cancer patients show a better overall survival than their malecounterparts. Chinese medical journal 2010, 123(17):2347-2352.

    22. Wang XX, ZhouZM, Yuan ZY, Zhang DS, Shi YX, Jiang WQ: [Efficacy of docetaxel combinedcapecitabine on metastatic breast cancer]. Chin J Cancer 2007,26(4):407-410.

    23. Yuan ZY, Wang SS, Gao Y, Su ZY, Luo WB, Guan ZZ: Clinicalcharacteristics and prognosis of triple-negative breast cancer: a report of 305cases. Chin J Cancer 2008, 27(6):561-565. 

    Yan-Xia Shi
    Title Associate professor
    Profile

    2008----present Associate professor. Medical Breast Cancer Department, Cancer Center, Sun Yat-Sen University. August 2004----2007 Attending Doctor and lecturer, Medical Oncology Department, Cancer Center, Sun Yat-Sen University. Secretary of Expert Panel in Good Clinical Practice Center, Cancer Center, Sun Yat-Sen University.Secretary of medical department, Cancer Center, Sun Yat-Sen University.Secretary of Expert Panel in Medical Record Administration, Cancer Center, Sun Yat-Sen University.

    Journal Reviewer
    2010 Chinese Journal of Cancer

    2009 Chinese Journal of CancerJournal Editor

    2009 Global oncology express

    Honors and Awards
    2007 The Best Service Award of Cancer Center, Sun Yat-Sen University

    2006 Excellent Paper Awards, the Fourth Chinese Conference on Oncology.

    1993 The Best Service Award of First hospital of Xu zhou Mineral Bureau

    1992 The Third rank Scholarship of Yangzhou Medical College.

    Associations and Memberships
    Member of Chinese Society of Clinical Oncology (CSCO).

    Member of Guangdong Provincial Anticancer Association (GDACA)

    Email
    Phone
    Research Interest(s)
    Education

    Ju2011 - Nov 2011 Harvard Medical School, Dana Farber Cancer Institute. Visiting Scholar .

    Fe2012 - Feb 2014  MD Anderson CancerCenter, Genomic Medicine Department. Visiting associate professor .

    Se2001 - July 2004, Sun Yat-sen University of Medical Sciences, Guangzhou, P.R. China, Ph.D.(Oncology)

    Se1998 - July 2001, Xu Zhou Medical College, Xu Zhou, P.R.China, Master(oncology).

    Se1989 - July 1992, Yang Zhou Medical College, Yang Zhou, P.R.China, Bachelor in Medicine(equivalent to M.D. in the US).

    Publications

    1. Deribe YL, ShiYX, Rai K, Nezi L, Akdemir KC, Amin SB, Wu CC, Zhong Y, Sadic D, MahdaviM, Protopopov A, Zhang J, Schotta G, Garraway L, Chin L. PREX2 integrates PTENsignaling to imprinted gene expression in cancer. Nature Cell Biology (under revision).

    2. Xia Q1, Cai Y, Peng R, Wu G, Shi YX*, Jiang W. The CDK1inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells toPARP inhibition. Int J Oncol. 2014 Mar;44(3):735-44.

    3. Cai Y, Xia Q, SuQG, Luo RZ, Sun YL, Shi YX*, Jiang WQ. mTOR inhibitor RAD001 (everolimus)induces apoptotic, not autophagic cell death in human nasopharyngeal carcinomacells.   Int J Mol Med.2013 Apr; 31(4):904-12.

    4. Shi YX, Tan YT, Yuan ZY, WangSS, Peng RJ, An X, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. Comparison of overall survivalbetween the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breastcancer. Med Oncol. 2012 Mar; 29(1):39-47.

    4. Jin Y, An X, Cai YC,Cao Y, Cai XY, Xia Q, Tan YT, Jiang WQ, ShiYX*. Zoledronic acid combined withchemotherapy bring survival benefits to patients with bone metastases fromnasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2011Oct;137(10):1545-51.

    5.Jin Y, Cai XY,Cai YC, Cao Y, Xia Q, Tan YT, Jiang WQ, ShiYX*. To build a prognostic score modelcontaining indispensible tumour markers for metastatic nasopharyngeal carcinomain an epidemic area.Eur J Cancer. 2012 Apr; 48(6):882-8.

    6. Jin Y, Cai YC, Cao Y, Cai XY, Tan YT, Shi YX*, Jiang WQ.Radiofrequency ablation combined withsystemic chemotherapy in nasopharyngeal carcinoma liver metastases improvesresponse to treatment and survival outcomes. J Surg Oncol. 2012 Sep1;106(3):322-6.

    7. Shi YX, Xia Q,Peng RJ, Yuan ZY, Wang SS, An X, Cao Y, Tan YT, Jin Y, Cai XY, Sun YL, Teng XY,Liu DG, Jiang WQ. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer.  JCancer Res Clin Oncol. 2012 Apr;138(4):705-14. Epub 2012 Jan 12.

    8. Cao Y, ShiYX(co-First), Chen JO, Tan YT, Cai YC, Luo HY, Qiu MZ, CaiXY, Jin Y, Sun YL, Jiang WQ. Serum C-reactive protein as animportant prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol. 2012 Aug; 33(4):1039-44.

    9. Jin Y, Cai XY, Shi YX, Xia XY, Cai YC, Cao Y, Zhang WD, HuWH, Jiang WQ.  Comparison of fivecisplatin-based regimens frequently used as the first-line protocols inmetastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012Oct;138(10):1717-25.

    11. ShiYX, Peng RJ, Lin SX, Wu QL, Lin TY, Sun XF, Huang HQ, Xia ZJ, Li YH, Xu RH, Liu DG, Guan ZZ, Jiang WQ.A survival of 103 cases of T-cell non-Hodgkin lymphoma. ZhonghuaNei Ke Za Zhi. 2007 Dec;46(12):1000-2. (in Chinese)

    12. Shi YX, Xu RH, Jiang WQ, Zhang L, Lin TY, Li YH, Xia ZJ, Luo HY, Han B, Wang F, He YJ, Guan ZZ. [Efficacy ofgemcitabine combined oxaliplatin on advanced pancreatic cancer. Chin JCancer 2007 Dec;26(12):1381-4. (in Chinese)

    13. Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ. Expression of CD16zeta in NK cells of B-cellnon-Hodgkin's lymphoma patients and in vitro killing effect of rituximabcombined lymphokine-activated killer cells on B-NHL cells. Chin J Cancer2007 Aug;26(8):837-42. (in Chinese)

    14. ShiYX, Zhang XS, Liu DG, Guan ZZ, Jiang WQ. Distribution of CD8+CD28- T cells andCD3+CD56+ NKT cells in peripheral blood of patients with B-cell non-Hodgkin'slymphoma. Chin J Cancer 2004 Nov;23 (11 Suppl):1437-42. (in Chinese)

    15. ShiYX, Zhang XS, Liu DG, Li YQ, Guan ZZ, Jiang WQ.CD4+CD25+T regulatory cells in peripheral blood of B-NHL patients with orwithout chemotherapy. Chin J Cancer 2004 May;23(5):597-601. (in Chinese)

    Feng Wang
    Title Associate Professor
    Profile

    Medical Training
    Sun Yat-sen University ,Fellowship
    Sun Yat-sen University, Residency
    The first affiliated hospital of Jiangxi Medical College, Internship

    Honors & Awards
    Outstanding Young Talents of Sun Yat-sen University Cancer Center
    Scholarship for Outstanding Oversea Students by the Chinese government
    New Stars of Science and Technology in Guangzhou

    Email
    Phone
    Research Interest(s)

    Research support

    01/01/2014 -12/31/2016
    National Natural Science Foundation of China
    The role and mechanism of reactive oxygen species and NFkB signaling pathway in glioblastoma stem cell aberrant differentiation.
    Role:PI

    01/01/2014 -12/31/2016
    Specialized Research Fund for the Doctoral Program of Higher Education01/01/2014.1-12/31/2016
    The effect and mechanism of reactive oxygen species modulating NFkB signaling pathway on aberrant differentiation in glioblastoma stem cell.
    Role:PI

    01/01/2014 -12/31/2015
    University of Texas MD Anderson Cancer Center Sister Institution Network Fund       
    AMPK directs the balance between mutant Kras and PI3K signaling and defines molecular subsets in colorectal cancer
    Role: Participant

    Education
    Degree-Granting Education
    The University of Texas Graduate School of Biomedical Sciences at Houston & MD Anderson Cancer Center, TX, USA, PHD, 2012, Biomedical Sciences
    Sun Yat-sen University, Guangzhou, China, MS, 2008, Oncology
    Nanchang University Medical College, Nanchang, China, MD, 2005, Medicine
                     
    Medical & Research Training 
    Medical Oncology Fellowship, Sun Yat-sen University Cancer Center, Guangzhou, China, 8/2012-Present
    Research Assistantship, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-6/2012
    Residency, Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, 9/2005-6/2008
    Internship, The first affiliated hospital of Jiangxi Medical College, Nanchang, China, 7/2004-6/2005
    Publications

    1.  Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H, Lee JS, Li XN, Xu RH, Huang P, Wang F. Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Res Ther. 2015; 6(1):198. (correspondence author).

    2.  Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, Luo HY, Zhang DS, Jin Y, Wang FH, Wang ZQ, Wang DS, Qiu MZ, Ren C, Li YH, Xu RH. Right- and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 2015;34(6):24.

    3.  Bai L, Wang F, Zhang DS, Li C, Jin Y, Wang DS, Chen DL, Qiu MZ, Luo HY, Wang ZQ, Li YH, Wang FH, Xu RH. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Sci Rep. 2015;5:17717. (co-first author).

    4.  Wei XL, Wang FH, Zhang DS, Qiu MZ, Ren C, Jin Y, Zhou YX, Wang DS, He MM, Bai L, Wang F, Luo HY, Li YH, Xu RH. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer. 2015;15:350.

    5.  Wei XL, Qiu MZ, Jin Y, Huang YX, Wang RY, Chen WW, Wang DS, Wang F, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH. Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer. 2015 Mar 31;112(7):1283-90.

    6.  Bai L, Zhang DS, Wu WJ, Ren C, Wang DS, Wang F, Qiu MZ, Xu RH. Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Med Oncol. 2015;32(2):469.

    7.  Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL, Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, Qiu MZ, Luo HY, Zhang DS, Xu RH. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol. 2014;20(48):18404-12.

    8.  Han J, Wang F, Yuan SQ, Guo Y, Zeng ZL, Li LR, Yang J, Wang DS, Liu MY, Zhao H, Liu KY, Liao JW, Zou QF, Xu RH. Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer. BMC Cancer. 2014;14(1):650. (co-first author).

    9.  Wang F, Wang FH, Bai L, Xu RH. Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. Onco Targets Ther. 2014;7:501-511.

    10.  Chen WW, Wang F, Chen S, Wang L, Ren C, Luo HY, Wang FH, Li YH, Zhang DS, Xu RH. Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma. Ann Thorac Surg. 2014;97(6):1975-81. (co-first author).

    11.  Chen WW, Wang F, Zhang DS, Luo HY, Wang ZQ, Wang FH, Qiu MZ, Ren C, Wei XL, Wu WJ, Li YH, Xu RH. Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases. BMC Cancer. 2014;14:222. (co-first author).

    12.  Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH, Xu RH. Identification of miR-214 as a negative regulator of colorectal cancer liver metastasis via regulation of FGFR1 expression. Hepatology. 2014 Mar 11. doi: 10.

    13.  He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol. 2014;20(1):264-73.

    14.  He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Jin Y, Wei XL, Xu RH. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer. PLoS One. 2013;8(12):e83921. (co-first author).

    15.  He MM, Wu WJ, Wang F, Wang ZQ, Zhang DS, Luo HY, Qiu MZ, Wang FH, Ren C, Zeng ZL, Xu RH. S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis. PLoS One. 2013;8(12):e82798. (co-first author).

    16.  Chen DL, Wang ZQ, Ren C, Zeng ZL, Wang DS, Luo HY, Wang F, Qiu MZ, Bai L, Zhang DS, Wang FH, Li YH, Xu RH. Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. J Transl Med. 2013;11(1):277.

    17.  Wei XL, Qiu MZ, Chen WW, Jin Y, Ren C, Wang F, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J Transl Med. 2013;11:249. doi: 10.1186/1479-5876-11-249.

    18.  Chen WW, Wang F, Xu RH. Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis. PLoS One. 2013;8(7):e68974. (co-first author).

    19.  Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, Keating MJ, Huang P. Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53-/- mouse model and primary human leukemia cells. Leukemia. 2014;28(1):118-28.

    20.  Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F, Li YH, Xu RH. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013;71(4):1065-72.

    21.  Wu WJ, Hu KS, Chen DL, Zeng ZL, Luo HY, Wang F, Wang DS, Wang ZQ, He F, Xu RH. Prognostic relevance of BRD7 expression in colorectal carcinoma. Eur J Clin Invest. 2013;43(2):131-40.

    22.  Yuan SQ, Wang F, Wang L, Chen G, Zhang H, Feng L, Colman H, Keating MJ, Xu RH, Wang JP, Huang P. Low mitochondrial respiration and high glycolytic metabolism in glioblastoma stem cells: a biochemical basis for new therapeutic strategies. Stem Cells. 2013 ;31(1):23-34. (co-first author).

    23.  Wang F, Yuan SQ, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, Rao HL, Xia Y, Jiang WQ, Huang HQ, Xia ZJ, Sun XF, Xu RH. High hepatits B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev. 2012; 21(3):261-7.

    24.  Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H,  Keating M, Liu J, McKeehan W, Wang HM, Luo Y, Huang P. Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy. PLoS Biol. In press.

    25.  Li ZH, Qiu MZ, Zeng ZL, Luo HY, Wu WJ, Wang F, Wang ZQ, Zhang DS, Li YH, Xu RH. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). J Transl Med. 2012; 10(1):21.

    26.  Chen G, Wang F, Trachootham D, Huang P. Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds. Mitochondrion. 2010; 10 (6): 614-25.

    27.  Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, Qiu MZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol Rep. 2010; 23(6): 1735-45.

    28.  Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, Zhou ZW, Chen XQ. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy. 2010;56(2):94-100.

    29.  Wang F, Ogasawara MA, Huang P. Small mitochondria-targeting molecules as anti-cancer agents. Mol Aspects Med. 2010; 31(1):75-92.

    30.  Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, Ajani JA, Huang P. Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal.2009; 11(5):1083-1095.

    31.  Li FH, Chen XQ, Luo HY, Li YH, Wang F, Qiu MZ, Teng KY, Li ZH, Xu RH. Prognosis of 84 intrahepatic cholangiocarcinoma patients. Chinese journal of Cancer.2009;28(5):528-532.

    32.  Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008; 8:115.

    33.  Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ.A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer. Chemotherapy.2008; 54(3):228-235.

    34.  Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, Lin TY, Huang HQ, Xia ZJ, Guan ZZ. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer, 2007;109:1360-1364.

    35.  Shi YX, Xu RH, Jiang WQ, Zhang L, Lin TY, Li YH, Xia ZJ, Luo HY, Han B, Wang F, He YJ, Guan ZZ. Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer. Ai Zheng. 2007; 26(12):1381-4.

    36.  Luo HY, Li YH, Zhang L, Jiang WQ, Shi YX, Wang F, He YJ, Xu RH. Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer. Ai Zheng.1007; 26:905-908.

    37.  Qiu MZ, Xu F, Wang SS, Luo HY, Wang F, Li FH, Sun XF, Xu GC, Lin TY, Huang HQ, Jiang WQ, Guan ZZ, Xu RH. Responses of 109 adult soft tissue sarcoma patients to chemotherapy. Ai Zheng. 2007; 26(12):1344-1349.

    38.  Han B, Xu RH, Shi YX, Li YH, Luo HY, Wang F, Hou JH, Cai MY, Jiang WQ. Expression and clinical significance of hypoxia-inducible factor-1alpha in gastric cancer. Ai Zheng. 2006; 25:1439-1442.

    Xia Yi
    Title Attending physician
    Profile
    Dr. Xia Yi is an attending physician of Medical Department of Oncology in Sun Yat-sen University Cancer Center. Dr.Xia obtained her Bachelor in Medicine and MD at Sun Yat-sen University of Medical Sciences, P. R. China in 2000 and 2009, respectively.Her research field is about clinical and basic research in medical oncology, especially in diagnosis and therapy for the lymphoma . Dr. Xia has published more than 10 research papers
    Email xiayi2046@163.com
    Phone 020-87343765
    Research Interest(s) Lymphoma, Carcinoma of Head and Neck.
    Education

    1995/09~2000/07 Sun Yat-sen University of Medical Science, Bachelor of medicine 

    2003/09~2009/06 Department of Medical Oncology, Cancer center of Sun Yat-sen University, Doctor of oncology

    Publications

    1. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS One. 2013 May 28;8(5):e64158.Li YJ, Li ZM, Xia Y,et al.

    2. Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma.BMC Cancer. 2013 May 3;13:222.Huang JJ, Li YJ, Xia Y, et al.

    3. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.Eur J Haematol. 2012 Jun;88(6):510-517.Li ZM, Huang JJ, Xia Y,et al.

    4. Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites.PLoS One. 2012;7(7):e41658.Li ZM, Huang JJ, Xia Y, et al.

    5. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.Chin J Cancer. 2012 Jul;31(7):342-7.Li ZM, Zhu YJ, Xia Y,et al.

    Xu Fei
    Title Attending Physician
    Profile
    Dr. Xu Fei is the attending physician of medical oncology in Sun Yat-sen University Cancer Center. She obtained her Bachelor in Medicine (equivalent to MD in the US) at Sun Yat-sen University of Medical Sciences, P. R. China in 2000. She got clinical internship training at the First affiliated hosipital of Sun Yat-sen University in 2000 and 2001. Then she joined the Department of Medical Oncology in July 2001 and worked to present. She obtained her PHD in Oncology at Sun Yat-sen University in 2011. She studied at Department of Clinical Oncology of the Chinese University of HONG KONG as visiting scholar in 2012 and 2013. She focus on breast cancer and Head & Neck Oncology treatment and prevention.
    Email
    Phone 8620-87342693
    Research Interest(s)
    Education

    2000 MD SUN-yat sen university of medical science, China 

    2011 PhD (oncology) Sun Yat-sen University Cancer Center, China

    Publications

    1. Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R,Liao H, Zhao HY, Zhang Y, Guan ZZ, Zhang L. Phase I and biodistribution studyof recombinant adenovirus vector-mediated herpes simplex virus thymidine kinasegene and ganciclovir administration in patients with head and neck cancer andother malignant tumors. Cancer Gene Ther. 2009 Sep;16(9):723-30.

    2. Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH,Zhao LP, Tian Y. Activation of Notch-1 enhances epithelial-mesenchymaltransition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem.2011 Dec 15. [Epub ahead of print]

    3. XuF, Tian Y, Huang Y, Zhang LL, Guo ZZ, Huang JJ, Lin TY. EGFR inhibitorssensitize non-small cell lung cancer cells to TRAIL-induced apoptosis. Chin JCancer. 2011 Oct;30(10):701-11.

    4. ZhaoYY, Xue C, Hou X, Liao H, Li S, Zhao HY, Huang Y, Chen LK, Xu F, Liu JL, ZhangL. Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acidversus chemotherapy alone for nasopharyngeal cancer patients with bonemetastases. Eur J Cancer. 2011 Apr;47(6):848-53.

    5. Zhang Y, Pan Z, Zhang X, Xu F, Zhang L. [K-RAS gene mutations inpatients with non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2010Jun;13(6):602-6. Chinese. 6.       Pu XX,Deng YH, Xu F, Xiao J, Guo HQ, Huang H, Tian Y, He YJ, Lin TY.[Effect of KRASmutation on efficacy of Cetuximab combined with chemotherapy in advancedcolorectal cancer patients]. Zhonghua Wei Chang Wai Ke Za Zhi. 2009Nov;12(6):594-7. Chinese.

    7. Huang H, Zhang Y, Zhao HY, Wang ZQ, Xu F,Xu GC, Zhang L, Guan ZZ. [Analysis of the efficacy and safety of gefitinib inthe treatment of recurrent advanced non-small cell lung cancer in an expandedaccess program (EAP)]. Zhonghua Zhong Liu Za Zhi. 2009 Feb;31(2):148-51.Chinese.

    8. Qiu MZ, Xu F, Wang SS, Luo HY,Wang F, Li FH, Sun XF, Xu GC, Lin TY, Huang HQ, Jiang WQ, Guan ZZ, Xu RH.[Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. AiZheng. 2007 Dec;26(12):1344-9. Chinese.

    9. ZhangL, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study ofgemcitabine in the treatment of patients with advanced nasopharyngeal carcinomaafter the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol.2008 Jan;61(1):33-8.

    10. Zhang Y, ZhangL, Xu F, Wang ZQ, Zhao HY, Guan ZZ, Xu GC, Pan ZK.  [Efficacy of gefitinib on advanced non-smallcell lung cancer in expanded access program (EAP)]. Ai Zheng. 2006Dec;25(12):1561-4. Chinese.

    11. Xu F,Zhang L, Xiang XJ, Wang ZQ, Zhou ZM, Wang SY. [High-dose induction therapyfollowed by maintenance with recombinant human erythropoietin for 30 patientswith tumor-related anemia]. Ai Zheng. 2006 Sep;25(9):1120-2. Chinese.

    12. Xiang XJ, He YJ, Li YH, Huang H, Xu F.[Clinical significance of survivin expression in peripheral T-cell lymphoma].Ai Zheng. 2006 Jun;25(6):758-61. Chinese.

    13. LiN, Wang B, Zhang X, Pan Z, Xu F, Wang Z, Zhang Y, Zhang L. [Tissue microarrayanalysis of HER2 protein expression in patients with non-small cell lungcancer.] Zhongguo Fei Ai Za Zhi. 2006 Feb 20;9(1):50-54. Chinese.

    Qiu Miao-zhen
    Title Attending doctor
    Profile
    Dr. Miao-zhen Qiu is an attending doctor in the department of medical oncology. Dr. Qiu obtained her Bachelor and Master Degree in Medicine (equivalent to MD in the US) at Sun Yat-sen University of Medical Sciences, P. R. China in 2006 and 2008, respectively. She is now in her second year for the PhD degree. After she graduated in 2007, she started to work in the department of medical oncology as a resident doctor (August 2008 to December 2011) and attending doctor (December 2011 till now). She is one of the members of the Chinese anti-cancer association in gastric cancer and one of the members of Chinese society of clinical oncology (CSCO).
    Email qiumzh@sysucc.org.cn
    Phone 020-87343351
    Research Interest(s) Chemotherapy and target therapy of gastrointestinal cancer; Drug resistance.
    Education

    Undergraduate

    9/01-6/06 Bachelor degree, Medical Science, Sun Yat-sen University

    Doctoral/graduate

    6/06-7/08 Master degree, Medical Oncology, Sun Yat-sen University

    9/12-present PhD, Oncology, Sun Yat-sen University

    Professional Experience (in chronological order, earliest first)

    8/08-12/11 Resident doctor, Department of medical oncology, Sun Yat-senUniversity

    12/11-presentAttending doctor, Department of medical oncology, Sun Yat-sen University
    Publications

    1. Qiu MZ, Lin JZ, Wang ZQ,Wang FH, Pan ZZ, Luo HY, Li YH, Zhou ZW, He YJ, Xu RH. Cut off value of

    carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levelsfor monitoring recurrence in

    patients with resectable gastric adenocarcinoma. Int J Biol Markers. 2009Oct-Dec;24(4):258-64

    2. Qiu MZ, Yuan ZY, Luo HY,Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH. Impact of pretreatment

    hematologic profile on survival of colorectal cancer patients. TumourBiol. 2010 Aug;31(4):255-60

    3. Qiu MZ, Xu RH, Ruan DY, Li ZH, Luo HY, Teng KY, Wang ZQ, Li YH,Jiang WQ. Incidence of anemia,

    leukocytosis, and thrombocytosis in patients with solid tumors in China.Tumour Biol.2010 Dec;31(6):633-

    41.

    4. Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ, Wang FH, Li YH, Xu RH.Expressions of hypoxia-inducible

    factor-1α and hexokinase-II in gastric adenocarcinoma: the impact onprognosis and correlation to

    clinicopathologic features. Tumour Biol. 2011 Feb;32(1):159-66.

    5. Qiu MZ, Li ZH, Zhou ZW, Li YH, Wang ZQ, Wang FH, Huang P, AzizF, Wang DY, Xu RH. Detection of

    Carcinoembryonic Antigen Messenger RNA in Blood using QuantitativeReal-Time Reverse Transcriptase-

    Polymerase Chain Reaction to Predict Recurrence of Gastric Adenocarcinoma.J Transl Med. 2010 Oct

    31;8:107.

    6. Teng KY, Qiu MZ (co-first author),Li ZH, Luo HY, Zeng ZL, Luo RZ, Zhang HZ, Wang ZQ, Li YH, Xu

    RH. DNA polymeraseeta protein expression predicts treatment response andsurvival of metastatic gastric

    adenocarcinoma patients treated with oxaliplatin-based chemotherapy. JTransl Med. 2010 Nov 27;8(1):126

    7. Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, Jiang WQ, XuRH. Prognostic analysis in nodenegative

    gastric cancer patients in China. Tumour Biol. 2011 Jun;32(3):489-92.

    8. Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, Jiang WQ, XuRH. Clinicopathological

    characteristics and prognostic analysis of gastric cancer in the youngadult in China. Tumour Biol. 2011

    Jun;32(3):509-14.

    9. Qiu MZ, Wang ZQ, Zhang DS, Liu Q, Luo HY, Zhou ZW, Li YH, JiangWQ, Xu RH. Comparison of 6th

    and 7th AJCC TNM staging classification for carcinoma of the stomach inChina. Ann Surg Oncol. 2011

    Jul;18(7):1869-76. Epub 2011 Jan 19.

    10. Qiu MZ, Zhang DS, Ruan DY, Luo HY, Wang ZQ, Zhou ZW, Wang FH,Li YH, Xu RH. A relationship

    between ABO blood groups and clinicopathologic characteristics of patientswith gastric adenocarcinoma in

    China. Med Oncol. 2011 Dec;28 Suppl 1:S268-73.

    11. Li ZH, Qiu MZ (co-first author), Zeng ZL, Luo HY, Wu WJ, Wang F, WangZQ, Zhang DS, Li YH, Xu RH.

    Copper-transporting P-type adenosine triphosphatase (ATP7A) is associatedwith platinum-resistance in nonsmall

    cell lung cancer (NSCLC). J Transl Med. 2012 Feb 3;10(1):21.

    12. Qiu MZ, Qiu HJ, Wang ZQ, Ren C, Wang DS, Zhang DS, Luo HY, LiYH, Xu RH. The tumor-log odds of

    positive lymph nodes-metastasis staging system, a promising new stagingsystem for gastric cancer after d2

    resection in china. PLoS One. 2012;7(2):e31736. Epub 2012 Feb 14.

    13. Yin Jin, Qiu MZ(co-first author),Wang DS, Zhang DS, Ren C, Bai L, Luo HY, Wang ZQ, Wang FH, Li YH,

    Xu RH. Adjuvant chemotherapy for elderly patients with gastric cancerafter d2 gastrectomy. PLoS One.

    2013;8(1):e53149.

    14. Qiu MZ, Cai MY, Zhang DS, et al. Clinicopathological characteristics and prognosticanalysis of Lauren

    classification in gastric adenocarcinoma in China. J Transl Med 2013;11:58.

    15. Wei XL, Qiu MZ (co-first author),Chen WW, et al. The status of HBV infection influences metastatic

    pattern and survival in Chinese patients with pancreatic cancer. J TranslMed. 2013 Oct 8;11(1):249.

    16. Qiu MZ, Li Q, Wang ZQ, et al. HER2-positive patients receivingtrastuzumab treatment have a comparable

    prognosis with HER2-negative advanced gastric cancer patients: Aprospective cohort observation. Int J

    Cancer. 2013 Oct 23. doi:10.1002/ijc28559.

    17. Qiu MZ, Wei XL, Zhang DS,et al. Efficacy and safety of capecitabine as maintenancetreatment after firstline

    chemotherapy using oxaliplatin and capecitabine in advanced gastricadenocarcinoma patients: a

    prospective observation. Tumour Biol. 2014 Feb 11

    18. Wei XL, Qiu MZ, Lin HX, et al. Patients with old age or proximal tumors benefit from metabolic syndrome

    inearly stage gastric cancer. PLoS One. 2014 Mar 5;9(3):e89965.
    Xue Hou
    Title Attending Physician
    Profile
    Dr. Xue Hou is an attending physician in Department of Medical Oncology of Sun Yat-sen University Cancer Center (SYSUCC). Dr. Hou obtained her Bachelor’s Degree in Medicine (equivalent to MD in the US) and Master’s Degree in Oncology at Sun Yat-sen University, P. R. China in 2004 and 2007, respectively. She was honored as Excellent Postgraduate Fellowship of Guangdong Province in 2007, Excellent Postgraduate Fellowship of Sun Yat-sen University in 2006, and Excellent Graduate of Sun Yat-sen University in 2004. After graduation in 2007, she worked in Lung Tumor Center of Shanghai Chest Hospital affiliated to Shanghai Jiaotong University from 2007 to 2011, and was honored as Excellent Young Talent of Shanghai Chest Hospital in 2010. She then rejoined the Department of Medical Oncology at Sun Yat-sen University Cancer Center in 2011.She is now a Ph.D. candidate, and receiving training at Memorial Sloan-Kettering Cancer Center (MSKCC) in the New York, U.S.A (the top 1 cancer center in the U.S.A). She was honored as Excellent Young Talent of SYSUCC in 2014. Dr Xue Hou is interested in the diagnosis, prognosis, and medical treatment of thoracic carcinoma, especially for lung cancer
    Email houxue@sysucc.org.cn
    Phone 86-20-87342470
    Research Interest(s)

    (1) Multidisciplinary and individualized chemotherapy and targeted therapy of thoracic cancers, including lung cancer, thymic carcinoma and mediastinal cancers; 

    (2) Translational research of lung cancer(3) Mechanism of cancer metastasis

    Education

    2014.8— present: Visiting investigator of MemorialSloan-Kettering Cancer Center (New York, USA);

    2013.8— present: Ph.D Candidate at the Department of MedicalOncology, Sun Yat-sen University Cancer Center;

    2004.9—2007.6: Postgraduate at the Department of MedicalOncology, Sun Yat-sen University Cancer Center, Master Degree;

    1999.9—2004.6:Sun Yat-sen University of Medical Sciences (Now Known as Medical College of SunYat-Sen University), Bachelor Degree of Clinical Medicine.
    Publications

    1.      Hou X, Fu JH, Wang X,Zhang LJ, Liu QW, Luo KJ, Lin P, YangHX. Prophylactic thoracic duct ligation has unfavorable impacton overall survival in patients with resectable oesophageal cancer. Eur J Surg Oncol. 2014 May 22. pii:S0748-7983(14)00447-8. doi: 10.1016/j.ejso.2014.05.002. [Epub ahead of print]PMID:24913091

    2.      Hou X, Wei JC, Fu JH, Wang X, Zhang LJ, Lin P, Yang HX. Proposed Modificationof the Seventh American Joint Committee on Cancer Staging System for EsophagealSquamous Cell Carcinoma in Chinese Patients. Ann Surg Oncol. 2014;21(1):337-42.

    3.      Hou X, Wei JC, Wu JX, Wang X, Fu JH, Lin P, Yang HX. Multidisciplinary modalitiesachieve encouraging long-term survival in resectable limited-disease esophagealsmall cell carcinoma. PLoS One. 2013;8(7):e69259.

    4.      Hou X, Wei JC, Xu Y,Luo RZ, Fu JH, Zhang LJ, Lin P, Yang HX. The positive lymph node ratio predictslong-term survival in patients with operable thoracic esophageal squamous cellcarcinoma in China. Ann Surg Oncol.2013;20:1653-9

    5.     Wu X, Liang WH, Hou X (co-firstauthor), Lin Z, Zhao HY, Huang Y, Fang WF, Zhao YY, Wu JX, Yang YP, XueC, Hu ZH, Zhang J, Zhang JW, Ma YX, Zhou T, Qin T, Zhang L. Serum proteomicstudy on EGFR-TKIs target treatment for patients with NSCLC. OncoTargets andTher. 2013; 6: 1481-1491.

    6.     Wu X, Huang PY, Peng PJ, Lu LX, Han F,Wu SX, Hou X, Zhao HY, Huang Y, Fang WF, Zhao YY, Xue C, Hu ZH,Zhang J, Zhang JW, Ma YX, Liang WH, Zhao C, Zhang L. Long-term follow-up of a phase III study comparingradiotherapy with or without weekly oxaliplatin for locoregionally advancednasopharyngeal carcinoma. Ann Oncol. 2013; 24(8):2131-6.

    7.     Dinglin XX, Huang Y, Liu H, Zeng YD, HouX, Chen LK. Pemetrexed and cisplatin combination with concurrent wholebrain radiotherapy in patients with brain metastases of lung adenocarcinoma: asingle-arm phase II clinical trial. J Neurooncol.2013; 112(3):461-6.

    8.     Yang HX, HouX (co-first author), Liu QW, Zhang LJ, Liu JG, Lin P, Fu JH. Tumor locationdoes not impact long-term survival in patients with operable thoracicesophageal squamous cell carcinoma in China. Ann Thorac Surg. 2012; 93:1861-6.

    9.      Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, Yang HX. High expression of thetranscriptional co-activator p300 predicts poor survival in resectablenon-small cell lung cancers. Eur J Surg Oncol. 2012, 38(6): 523-30.

    10.   LiangY, Hou X (co-first author), Cui Q, Kang TB, Fu JH, Zhang LJ, Luo RZ, He JH, ZengYX, Yang HX.Skp2 expression unfavorably impacts survival inresectable esophageal squamous cell carcinoma.J Transl Med.2012;10:73. doi: 10.1186/1479-5876-10-73.

    11.    Hou X, Zhao C, Guo Y,Han F, Lu LX, Wu SX, Li S, Huang PY, Huang H, Zhang L. Different ClinicalSignificance of Pre- and Post-treatment Plasma Epsteine-Barr Virus DNA Load inNasopharyngeal Carcinoma Treated with Radiotherapy. Clinical Oncology. 2011,23(2): 128-33.

    12.    ZhaoYY, Xue C, Hou X, Liao H, Li S, Zhao HY, Huang Y, Chen LK, Xu F,Liu JL, Zhang L. Changes of bone resorption marker (NTX) in chemotherapy pluszoledronic acid versus chemotherapy alone for nasopharyngeal cancer patientswith bone metastases. Eur J of Cancer. 2011; 47:848-853.

    13.   Zhang L, Hou X (co-first author), Lu S, Rao HL, Hou JH, Luo RZ, Huang H, Zhao HY, Jian HH, Chen ZW, Liao ML, Wang X.Predictive significance of bone sialoprotein and osteopontin for bonemetastases in resected Chinese non-small-cell lung cancer patients: a large cohortretrospective study. Lung Cancer. 2010; 67(1):114-119.

    14.    YangHX, Hou X (co-first author), Lin P, Yang H, Zeng CG, Rong TH, FuJH. Peripheral direct adjacent lobe invasion non-small celllung cancer has a similar survival to that of parietal pleural invasion T3disease. J Thorac Oncol. 2009;4:1342-6.

    15.   Yang HX, Hou X (co-first author),Lin P, Rong TH, Yang H, Fu JH. Survival and risk factors of surgically treatedmediastinal invasion T4 non-small cell lung cancer. AnnThorac Surg. 2009;88:372-8.

    16.    YangHX, Hou X (co-first author), Lin P, Rong TH, Yang H, Fu JH.Aprognostic analysis of N0-1M0 intralobar metastatic non-small cell lung cancer.ZhonghuaYi Xue Za Zhi. 2009;89:2486-9. Chinese. PMID: 20137436

    17.    Yang HX, Hou X (co-first author),Lin P, Rong TH, Yang H, Fu JH.Postoperative survival comparison of non-smallcell lung cancer between disease with peripheral direct adjacent invasion andresectable T4 disease with mediastinal structures invasion. Zhonghua Yi Xue ZaZhi. 2009;89:1770-3. Chinese. PMID: 19862983

    18.    Hou X, Zhang L, Zhao C, Li S, LuLX, Han F, Shao JY, Huang PY. Prognostic impact of plasma Epstein-Barr virusDNA concentration on distant metastasis in Nasopharyngeal Carcinoma. ChineseJournal of Cancer. 2006; 25(7):785-792. Chinese.PMID: 16831265

     

    Luo Hui-yan
    Title Doctor
    Profile

    2000/08-2004/08   
    Department of respiration medicine, Affiliated hospital of Guilin Medical College, Resident   and  attending physician

    2004/09-2007/06   
    Department of MedicalOncology, Cancer center of Sun Yat-sen University,Master of oncology

    2007/07-2010/07 
    Department of Medical Oncology, Cancer center of Sun Yat-senUniversity, Oncology training Physician

    2010/08-Present   
    Department of Medical Oncology, Cancer center of Sun Yat-sen University, Attending Physician

    Email luohy@sysucc.org.cn
    Phone 020-87452490
    Research Interest(s)

    Clinical and basic research inmedical oncology and translational medicine,especially in diagnosis and therapy for the gastrointestinal tumor.

    Education

    1995/09-2000/07    Faculty of Clinical medicine in Guangxi Medical  University, Bachelor of medicine

    2004/09-2007/06    Department of Medical Oncology, Cancer center of Sun Yat-sen University, Master ofoncology

    2007/07-2010/07    Department of Medical Oncology, Cancer center of  Sun Yat-senUniversity, Oncology training Physician

    2012.9-Present       PhD candidate

    Publications

    1.       Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, Xu RH. Overexpression of the circadian clock gene bmal1increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 2014 Feb 15;20(4):1042-52.

    2.       Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH.Comparison of the prognostic values of various inflammation based factors inpatients with pancreatic cancer. Med Oncol. 2012Dec;29(5):3092-100.

    3.        Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, RuanDY, He YJ, Li YH, Xu RH. Phase 2 study of capecitabine and irinotecancombination chemotherapy (modified XELIRI regimen) in patients with advancedgastric cancer. Am J Clin Oncol. 2011 Dec;34(6):555-60.

    4.       Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, JiangWQ, Xu RH. Prognostic analysis in node-negative gastric cancer patients inChina.Tumour Biol. 2011 Jun;32(3):489-92.

    5.       Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, XuRH.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectalcancer. World J Gastroenterol. 2010 Dec 14;16(46):5881-8.

    6.       Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ, Wang FH, LiYH, Xu RH. Expressions of hypoxia-inducible factor-1α and hexokinase-II ingastric adenocarcinoma: the impact on prognosis and correlation toclinicopathologic features.Tumour Biol. 2011 Feb;32(1):159-66.

    7.        Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, QiuMZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH.Cetuximab enhances the effect ofoxaliplatin on hypoxic gastric cancer cell lines.Oncol Rep. 2010Jun;23(6):1735-45.

    8.        Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, ZhouZW, Chen XQ.Phase II trial of XELOX as first-line treatment for patients withadvanced gastric cancer. Chemotherapy. 2010;56(2):94-100.

    9.       Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ,Xu RH.Phase II study of capecitabine plus oxaliplatin (XELOX) as first-linetreatment and followed by maintenance of capecitabine in patients withmetastatic colorectal cancer.J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10. 

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.